Protein degradation agent

By developing a compound that can efficiently degrade c-Myc and other related proteins, the problem of poor inhibition of c-Myc protein in the prior art is solved, and an effective treatment plan for a variety of high-expression diseases is provided.

WO2024027694A9PCT designated stage expired Publication Date: 2025-01-02SUZHOU KINTOR PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/110514
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-20
Filing Date
2023-08-01
Publication Date
2025-01-02

AI Technical Summary

Technical Problem

Existing methods have poor activity in inhibiting the function of c-Myc proteins and cannot effectively prevent or alleviate the high-expression diseases of various proteins associated with c-Myc dysregulation.

Method used

A c-Myc protein degrader has been developed, which is capable of efficiently degrading proteins including c-Myc, N-myc, GSPT1, CK1α, IKZF (1/2/3), AR and AR-V7 for treatment and These protein disorders are associated with disorders.

Benefits of technology

By efficiently degrading target proteins, a more effective treatment is provided that can prevent or alleviate diseases associated with disorders of these proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023110514_02012025_PF_FP_ABST
    Figure CN2023110514_02012025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention and treatment of diseases related to disorders of various proteins including c-Myc protein, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

A protein degrader

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of Chinese Application No. 2022109163085, filed on August 1, 2022, and Chinese Application No. 2022116406452, filed on December 20, 2022. The entire contents of said Chinese Application Nos. 2022109163085 and 2022116406452 are hereby incorporated by reference herein. Technical Field

[0003] The present invention belongs to the field of medicine, and in particular relates to a protein degradation agent, a preparation method and use thereof. Background Art

[0004] The naturally disordered protein c-Myc is a well-known transcription factor that regulates approximately 15% of human genes. c-Myc regulates a variety of biological functions, such as cell proliferation, apoptosis, cell cycle progression, cellular metabolism, and embryonic development, and plays a crucial role in the development, progression, and progression of diseases.

[0005] Numerous studies have shown that c-Myc is closely associated with a variety of tumor diseases, including lymphoma, breast cancer, prostate cancer, colon cancer, cervical cancer, multiple myeloma, myeloid leukemia, melanoma, osteosarcoma, malignant glioma, small cell lung cancer, and medulloblastoma. c-Myc can promote tumor development and growth in multiple ways (C Yu, et al. Sci Rep 6.1, 1-11).

[0006] In addition to cancer, c-Myc is also associated with several other diseases. For example, in diabetes, increased c-Myc expression is associated with dedifferentiation or apoptosis of insulin-producing pancreatic β-islet cells, leading to a decrease in insulin secretion (Magid R et al. J Biol Chem, 2003, 278:32994). In the monoclonal hypothesis of atherosclerosis, increased c-Myc expression in vivo is associated with the development of aortic and carotid plaques. Indeed, activation of c-Myc-dependent signaling pathways has been found in early coronary artery lesions in the Watanabe hyperlipidemic rabbit model and in early coronary artery wall lipid accumulation in hypercholesterolemic pigs. More importantly, antioxidants downregulate c-Myc overexpression in a manner similar to that observed in tumor cells (Prasad KN et al. Biochem Cell Biol 68, 1250-55).

[0007] The c-Myc protein has become one of the most attractive potential anti-tumor targets. Currently, there are two main approaches reported to inhibit c-Myc protein function. The first is direct inhibition of c-Myc protein function, including inhibition of the Myc / Max dimer and the Myc / Max / E-box trimer binding; the second is the elimination or degradation of c-Myc protein.

[0008] The transcription factor terminator (G1 to S phase transition 1, GSPT1) mediates the recognition of stop codons and promotes the release of transcribed peptide chains from ribosomes. In addition to playing a role in the process of transcription termination, GSPT1 is also closely related to a variety of important cellular activities such as cell cycle regulation, cytoskeleton formation, and apoptosis. GSPT1 is considered to be a carcinogenic factor for many tumors, including breast cancer, liver cancer, gastric cancer, and prostate cancer (Cui, Jian, et al. International journal of oncology, 2020, 56(4):867-878).

[0009] Casein kinase 1α (CK1α) can phosphorylate p53. As a tumor suppressor protein, p53 participates in multiple intracellular signal transduction pathways and plays a crucial role in processes such as cell cycle regulation and apoptosis. Phosphorylated p53 can bind to mouse double minute gene 2 (MDM2), leading to ubiquitination and degradation (Huart, Anne-Sophie, et al. Journal of Biological Chemistry 284.47(2009):32384-32394). Therefore, blocking CK1α activity can stabilize p53, thereby exerting its tumor suppressor activity.

[0010] Zinc finger transcription factors IKZF1 / 2 / 3 (Aiolos, Helios, Ikaros) belong to the Ikaros zinc-finger (IKZF) family and are crucial for the survival of lymphoid cells. For example, Aiolos binds to the B lymphocytic neoplasia gene 2 (Bcl-2) enhancer, thereby upregulating the Bcl-2 protein's effects on cell survival. Aberrant activation of Helios and Ikaros can upregulate Bcl-XL expression, driving the development and progression of various hematologic malignancies.

[0011] Current methods generally have the disadvantage of poor activity. To meet this unmet clinical need, the applicant has developed a series of compounds that can efficiently clear c-Myc protein, which can be used to treat diseases related to the overexpression of various proteins including c-Myc.

[0012] Summary of the Invention

[0013] The present invention aims to provide a c-Myc protein degrader, a preparation method and use thereof. The compound of the present invention can be used to degrade a variety of proteins including c-Myc protein, such as N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7, thereby preventing, alleviating or treating diseases related to the disorder of these proteins.

[0014] In some embodiments, the present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0015] in,

[0016] R1 is selected from: a (CH2) a -、R a (CH2) a C(=O)-、R a (CH2) a NHC(=O)-、R a (CH2) a OC(=O)- or R a (CH2) a S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace;

[0017] Q is selected from: -NR2-, -O-,

[0018] R2 is selected from: hydrogen, R b -、R b C(=O)-、R b S(=O)2-、R 14 ;

[0019] Ring A represents a heterocycloalkyl group containing at least one N atom as a heteroatom, which is connected to T or R1 through the N atom (i.e., when the nitrogen atom in ring A is connected to T, the other connection point in ring A is connected to R1; conversely, when it is connected to R1, the other connection point in ring A is connected to T), and ring A is optionally substituted with one or more groups selected from R9;

[0020] R a 、R b Selected from: C1-C8 alkyl, C3-C 10 Cycloalkyl, C3-C 10 Bridged ring group, -NR 11 R 12 、C3-C 10Any containing O, S, SO2, N or NHC(=O)R 22 wherein the C1-C8 alkyl group is a heterocyclic group, an aryl group, a heteroaryl group, a fused arylcycloalkyl group, a fused arylheterocyclic group, a fused heteroarylcycloalkyl group, a fused heteroarylheterocyclic group, an aryl-aryl group, an aryl-heteroaryl group, a heteroaryl-aryl group, a heteroaryl-heteroaryl group, an aryl-alkyl group, a heteroaryl-alkyl group, an aryl-cycloalkyl group, an aryl-heterocyclic group, a cycloalkyl-heterocyclic group, a heterocyclic group-heterocyclic group, and any two CC groups in the C1-C8 alkyl group may be inserted with a group selected from the group consisting of -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, -NHS(=O)2-, and R a Optionally substituted with one or more R9, R b Optionally one or more R 10 replace;

[0021] T, U, and Z are independently selected from the group consisting of: chemical bonds, N, O, carbonyl, C1-C6 alkylene, C3-C 10 Cycloalkylene, arylene, heteroarylene, heterocyclylene, wherein the alkylene, cycloalkylene, arylene, heteroarylene, heterocyclylene is optionally substituted by one or more R9;

[0022] Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-O(CH2) b -、-NR2(CH2) b -, the "CH2" is optionally substituted by one or more R9, or is optionally substituted by -CH2CH2-, the "NH" is optionally substituted by R 14 replace;

[0023] L is selected from: -(CR7R8) o -, -C(=O)-;

[0024] R3-R5, R7-R9 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, hydroxyl, thiol, nitro, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R3-R5, R7-R9 are multiple, any two adjacent groups may be combined to form a ring;

[0025] R 10 Selected from: hydrogen, halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R 10 In the case of multiple, any two adjacent ones can combine to form a ring;

[0026] R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-C(=O)R n 、-C(=O)OR n 、-OC(=O)R n 、-NR m Rn 、-C(=O)NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-S(=O)2R n 、-S(=O)2NR m R n 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0027] R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0028] R n Selected from: C1-C8 alkyl substituted by hydroxy, thiol or amino, wherein any two CCs in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted by 1-3 groups selected from halogen, cyano, amino, nitro or C1-C3 alkoxy;

[0029] R m Independently selected from: hydrogen, C1-C8 alkyl, any two CC in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted with 1-3 groups selected from halogen, hydroxy, cyano, amino, nitro, or C1-C3 alkoxy;

[0030] R6 is selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted by 1-3 halogen, hydroxyl, cyano, amino, nitro, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 、-C(=O)NHR 23 , C1-C3 alkyl, C 1- C3 alkoxy or -OP(=O)(OM)2 group substitution;

[0031] M is independently selected from: hydrogen, C1-C4 alkyl;

[0032] R 11 、R 12 Each is independently selected from: hydrogen, C1-C4 alkyl, aryl, aryl-alkyl;

[0033] R 21 Selected from: chemical bonds, C1-C4 alkylene;

[0034] R 22 、R 23 Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, aryl, and aryl-alkyl, wherein the C1-C4 alkyl, aryl, and aryl-alkyl are optionally substituted by a group selected from halogen, hydroxy, and amino;

[0035] a is selected from: 0, 1, 2, 3, 4 or 5;

[0036] b is selected from: 0, 1, 2, 3, 4 or 5;

[0037] n is selected from: 0, 1, 2 or 3;

[0038] m is selected from: 0, 1, 2, 3 or 4;

[0039] oChoose from: 1 or 2.

[0040] Preferably, the compound represented by formula (I) contains at least one selected from R 13 or R 14 group.

[0041] Preferably, the compound represented by formula (I) is not:

[0042] In some embodiments, the present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0043] in,

[0044] R1 is selected from: a (CH2) a -、R a (CH2) a C(=O)-、R a (CH2) a NHC(=O)-、R a (CH2) a OC(=O)- or R a (CH2) a S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace;

[0045] Q is selected from: -NR2-, -O-,

[0046] R2 is selected from: hydrogen, R b -、R b C(=O)-、R b S(=O)2-、R 14 ;

[0047] Ring A represents a heterocycloalkyl group containing at least one N atom as a heteroatom, which is connected to T via the N atom, and Ring A is optionally substituted by one or more groups selected from R9;

[0048] R a 、R b Selected from: C1-C8 alkyl, C3-C 10 Cycloalkyl, C3-C 10 Bridged ring group, -NR 11 R 12 、C3-C 10 Any containing O, S, SO2, N or NHC(=O)R 22 The C1-C8 alkyl group may be a heterocyclic group, an aryl group, a heteroaryl group, a fused arylcycloalkyl group, a fused arylheterocyclic group, a fused heteroarylcycloalkyl group, a fused heteroarylheterocyclic group, an aryl-alkyl group, a heteroaryl-alkyl group, an aryl-cycloalkyl group, an aryl-heterocyclic group, a cycloalkyl-heterocyclic group, a heterocyclic group-heterocyclic group, and any two CC groups in the C1-C8 alkyl group may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and R a Optionally substituted with one or more R9, R b Optionally one or more R 10replace;

[0049] T, U, and Z are independently selected from the group consisting of: chemical bonds, carbonyl groups, C1-C6 alkylene groups, C3-C 10 Cycloalkylene, arylene, heteroarylene, heterocyclylene, wherein the alkylene, cycloalkylene, arylene, heteroarylene, heterocyclylene is optionally substituted by one or more R9;

[0050] Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-O(CH2) b -、-NR2(CH2) b -, the "CH2" is optionally substituted by one or more R9, or is optionally substituted by -CH2CH2-, the "NH" is optionally substituted by R 14 replace;

[0051] L is selected from: -(CR7R8) o -, -C(=O)-;

[0052] R3-R5, R7-R9 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R3-R5, R7-R9 are multiple, any two adjacent groups may be combined to form a ring;

[0053] R 10 Selected from: hydrogen, halogen, cyano, amino, nitro, -R 21C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R 10 In the case of multiple, any two adjacent ones can combine to form a ring;

[0054] R 13 Selected from: hydroxyl, R n 、-OR n 、-C(=O)R n 、-C(=O)OR n 、-OC(=O)R n 、-NR m R n 、-C(=O)NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-S(=O)2R n 、-S(=O)2NR m R n 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0055] R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m Rn 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0056] R n Selected from: C1-C8 alkyl substituted by hydroxy, wherein any two CCs in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted with 1-3 groups selected from halogen, cyano, amino, nitro, or C1-C3 alkoxy;

[0057] R m Independently selected from: hydrogen, C1-C8 alkyl, any two CC in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted with 1-3 groups selected from halogen, hydroxy, cyano, amino, nitro, or C1-C3 alkoxy;

[0058] R6 is selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted by 1-3 halogen, hydroxyl, cyano, amino, nitro, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 、-C(=O)NHR 23 , C1-C3 alkyl, C 1- C3 alkoxy or -OP(=O)(OM)2 group substitution;

[0059] M is independently selected from: hydrogen, C1-C4 alkyl;

[0060] R 11 、R 12 Each is independently selected from: hydrogen, C1-C4 alkyl, aryl, aryl-alkyl;

[0061] R 21 Selected from: chemical bonds, C1-C4 alkylene;

[0062] R 22 、R 23 Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, aryl, and aryl-alkyl, wherein the C1-C4 alkyl, aryl, and aryl-alkyl are optionally substituted by a group selected from halogen, hydroxy, and amino;

[0063] a is selected from: 0, 1, 2, 3, 4 or 5;

[0064] b is selected from: 0, 1, 2, 3, 4 or 5;

[0065] n is selected from: 0, 1, 2 or 3;

[0066] m is selected from: 0, 1, 2, 3 or 4;

[0067] o Select from: 1 or 2;

[0068] Wherein, the compound represented by formula (I) contains at least one selected from R 13 or R 14 group.

[0069] Preferably, the compound is not:

[0070] In the present invention, preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH. Preferably, R m Selected from: hydrogen, -C1-C4 alkyl.

[0071] In the present invention, preferably, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n is selected from the group consisting of: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH. Preferably, R m Selected from: hydrogen, -C1-C4 alkyl.

[0072] In some embodiments, the R1 is selected from: R a C(=O)-、R a CH2C(=O)-、R a CH2CH2C(=O)-、R a -、R a CH2-、R a CH2CH2-、R a NHC(=O)-、R a CH2NHC(=O)-、R a CH2CH2NHC(=O)-、R a OC(=O)-、R a CH2OC(=O)-、R a CH2CH2OC(=O)-、R a S(=O)2-、R a CH2S(=O)2-、R a CH2CH2S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace.

[0073] Preferably, the R1 is selected from: R a C(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-、R a CHR9CH2-、R a CHCHR9-、R a NR 14 C(=O)-、R a CHR9NHC(=O)-、R a CHNR 14 C(=O)-、R a CHR9CH2NHC(=O)-、R a CH2CHR9NHC(=O)-、R a CH2CH2NR 14 C(=O)-、R a OC(=O)-、R a CHR9OC(=O)-、R a CHR9CH2OC(=O)-、R a CH2CHR9OC(=O)-、R a CHR9S(=O)2-、Ra CHR9CH2S(=O)2-、R a CH2CHR9S(=O)2-.

[0074] Preferably, said R9 is selected from: hydrogen, C1-C4 alkyl, R 13 More preferably, the R9 is selected from: R 13 .

[0075] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n .

[0076] Preferably, the R 14 Selected from: R n 、-C(=O)R n .

[0077] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0078] In some embodiments, the R1 is selected from: R a C(=O)-、R a CH2C(=O)-、R a CH2CH2C(=O)-、R a -、R a CH2-、R a CH2CH2-、R a NHC(=O)-、R a CH2NHC(=O)-、R a CH2CH2NHC(=O)-、R a OC(=O)-、R a CH2OC(=O)-、R a CH2CH2OC(=O)-、R a S(=O)2-、R a CH2S(=O)2-、R a CH2CH2S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace.

[0079] Preferably, the R1 is selected from: R aC(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-、R a CHR9CH2-、R a CHCHR9-、R a NR 14 C(=O)-、R a CHR9NHC(=O)-、R a CHNR 14 C(=O)-、R a CHR9CH2NHC(=O)-、R a CH2CHR9NHC(=O)-、R a CH2CH2NR 14 C(=O)-、R a OC(=O)-、R a CHR9OC(=O)-、R a CHR9CH2OC(=O)-、R a CH2CHR9OC(=O)-、R a CHR9S(=O)2-、R a CHR9CH2S(=O)2-、R a CH2CHR9S(=O)2-.

[0080] Preferably, R9 is selected from: hydrogen, C1-C4 alkyl, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 More preferably, the R9 is selected from: R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 .

[0081] Preferably, the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n .

[0082] Preferably, the R 14 Selected from: R n 、-C(=O)R n .

[0083] Preferably, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0084] In some embodiments, the R a is selected from the group consisting of: phenyl, naphthyl, carbazolyl, 1-azacarbazolyl, 2-azacarbazolyl, 1,8-diazacarbazolyl, indolyl, 7-azaindolyl, 2,3-dihydroindolyl, 2,3-dihydro-7-azaindolyl, phenoxazinyl, fluorenyl, quinolyl, isoquinolyl, naphthyridinyl, tetrahydronaphthyridinyl, tetrahydroquinolyl, pyrimidinyl, triazolyl, bicyclo[1.1.1]pentanyl, norbornyl, and adamantyl. Preferably, R a Optionally substituted with one or more R9 selected from hydrogen, R 13 , halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

[0085] Preferably, the R a Selected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazol-9-yl, 1-azacarbazol-9-yl, 2-azacarbazol-9-yl, 1,8-diazacarbazol-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazin-10-yl, fluoren-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl , isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl. Preferably, R a Optionally substituted with one or more R9 selected from: R 13, F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl.

[0086] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m More preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0087] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: hydroxy substituted C1-C4 alkyl; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0088] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0089] Preferably, R9 is selected from: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -NHCH2OH, -NHCH2CH2OH, -NHCH2CH2OH, -NHCH2CH2OH, -N(CH3)CH2OH, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2CH2OH, -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH.

[0090] Preferably, the R a Selected from the following groups:

[0091] In some embodiments, the R a is selected from the group consisting of: phenyl, naphthyl, carbazolyl, 1-azacarbazolyl, 2-azacarbazolyl, 1,8-diazacarbazolyl, indolyl, 7-azaindolyl, 2,3-dihydroindolyl, 2,3-dihydro-7-azaindolyl, phenoxazinyl, fluorenyl, quinolyl, isoquinolyl, naphthyridinyl, tetrahydronaphthyridinyl, tetrahydroquinolyl, pyrimidinyl, pyridyl, quinolyl-pyridyl, triazolyl, bicyclo[1.1.1]pentanyl, norbornyl, and adamantyl. Preferably, R a Optionally substituted with one or more R9 selected from hydrogen, hydroxy, thiol, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 , halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

[0092] In some specific embodiments, the R a is selected from: isoquinolinyl-pyridyl. Preferably, the R a Optionally substituted with one or more R9 selected from hydrogen, hydroxy, thiol, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13, halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

[0093] Preferably, the R a Selected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazol-9-yl, 1-azacarbazol-9-yl, 2-azacarbazol-9-yl, 1,8-diazacarbazol-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazin-10-yl, fluoren-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl -8-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5-(8-quinolin-yl)-pyridin-2-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl. Preferably, R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl.

[0094] In some specific embodiments, the R a Selected from: 5-(1-isoquinolin-yl)-pyridin-2-yl. Preferably, R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl.

[0095] Preferably, the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R mMore preferably, the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0096] Preferably, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0097] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0098] Preferably, R9 is selected from the group consisting of: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, thiol, amino, -C(=O)CH3, C(=O)CH2CH 3、 C(=O)CH2CH2CH 3、-CH2CH2N(CH3)2, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH 2SH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -OCH2NH2, -OCH2CH2NH2, -OCH2CH2CH2NH2, -OCH2SH, -OCH2CH2SH, -OCH2CH2CH2SH, -NHCH2OH, -NHCH2 CH2OH, -NHCH2CH2CH2OH, -NHCH2NH2, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2SH, -NHCH2CH2SH, -NHCH2CH2CH2SH, -N(CH3)CH2OH, -N(CH3)CH2CH 2OH, -N(CH3)CH2CH2CH2OH, -N(CH3)CH2NH2, -N(CH3)CH2CH2NH2, -N(CH3)CH2CH2CH2NH2, -N(CH3)CH2SH, -N(CH3)CH2CH2SH, -N(CH3)CH2CH2CH2SH 、 -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(COCH3)CH2NH2, -N(COCH3)CH2CH2NH2, -N(COCH3)CH2CH2CH2NH2, -N(COCH3)CH2SH, -N(COCH3)CH2C H2SH, -N(COCH3)CH2CH2CH2SH-N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH, -N(SO2CH3)CH2NH2, -N(SO2CH3)CH2CH2NH2, -N(SO2CH3)CH2CH2CH2NH 2、 -N(SO2CH3)CH2SH, -N(SO2CH3)CH2CH2SH, -N(SO2CH3)CH2CH2CH2SH.

[0099] Preferably, the R a Selected from the following groups:

[0100] In some specific embodiments, the R a Selected from the following groups:

[0101] In some embodiments, Q is selected from: -NR2-,

[0102] Preferably, said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; more preferably, R2 is selected from the group consisting of: R 14 .

[0103] Preferably, the R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n .

[0104] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R n In some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0105] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0106] Therefore, preferably, the R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2O H, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -S(=O)2 CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH. In some embodiments, the R2 is further selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O) CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C(=O)O CH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、-C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2S H, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2 , -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2 CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

[0107] Preferably, the Select one of the following structures:

[0108] wherein each R9 is independently selected from: hydrogen, R 13 , halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy;

[0109] Each a1 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, each a2 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, each a3 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, each a4 is independently selected from: 0, 1, 2, 3, 4, 5, 6, each a5 is independently selected from: 0, 1, 2, 3, 4, 5.

[0110] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NRm -S(=O)2R n 、-NR n -S(=O)2R m ; Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n .

[0111] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, R n Selected from: hydroxy substituted C1-C4 alkyl; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0112] In some specific embodiments, the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0113] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0114] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0115] Preferably, the Select one of the following structures:

[0116] In some embodiments, T and Z are independently selected from: a chemical bond, a carbonyl group, a C1-C6 alkylene group or a C3-C 10 Cycloalkylene, the C1-C6 alkylene, C3-C 10 The cycloalkylene group is optionally substituted with one or more R9.

[0117] Preferably, T and Z are independently selected from: a chemical bond, a carbonyl group, a methylene group, a 1,2-ethylene group, a 1,1-cyclopropylene group or a 2,2-propylene group, and the methylene group, the 1,2-ethylene group or the 1,1-cyclopropylene group is optionally substituted by one or more R9.

[0118] Preferably, said R9 is selected from: hydrogen, R 13 , C1-C6 alkyl or C3-C8 cycloalkyl. Further preferably, R9 is selected from: hydrogen, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 , C1-C6 alkyl or C3-C8 cycloalkyl.

[0119] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n .

[0120] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0121] In some specific embodiments, the R9 is selected from: hydrogen, hydroxyl, thiol, amino, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 , C1-C6 alkyl or C3-C8 cycloalkyl; said R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ; the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R nSelected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n In some embodiments, U is selected from the group consisting of: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH. In some embodiments, U is selected from the group consisting of: C1-C6 alkylene, C3-C 10 Cycloalkylene, arylene or heteroarylene, wherein the alkylene, cycloalkylene, arylene or heteroarylene is optionally substituted by one or more R9.

[0122] Preferably, U is selected from the group consisting of: C2-C6 alkylene, C5-C6 cycloalkylene, C6-C 10 Arylene, 5-6 membered monocyclic heteroarylene, said alkylene, cycloalkylene, arylene, heteroarylene are optionally substituted by one or more R9.

[0123] Preferably, U is selected from the group consisting of 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,3-cyclopentylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,5-pyridylene, 2,5-pyrimidylene, 2,5-thiazolylene or 2,4-oxazolylene, and the 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,3-cyclopentylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,5-pyridylene, 2,5-pyrimidylene, 2,5-thiazolylene and 2,4-oxazolylene are optionally substituted with one or more R9.

[0124] Preferably, said R9 is selected from: hydrogen, R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy.

[0125] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2Rn 、-NR n -S(=O)2R m More preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0126] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, R n Selected from: hydroxy substituted C1-C4 alkyl; most preferably, R n In some embodiments, the R n Selected from: C1-C8 alkyl substituted with hydroxyl, mercapto or amino.

[0127] In some specific embodiments, the R9 is selected from: hydrogen, amino, hydroxyl, thiol, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy; the R 13 Selected from: hydroxyl, amino, thiol, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; preferably, the R nSelected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0128] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0129] Therefore, preferably, R9 is selected from: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -NHCH2OH, -NHCH2CH2OH, -NHCH2CH2OH, -NHCH2CH2OH, -N(CH3)CH2OH, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2CH2OH, -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH. In some embodiments, R9 is selected from the group consisting of: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxy, thiol, amino, -C(=O)CH3, C(=O)CH2CH 3、 C(=O)CH2CH2CH 3、-CH2CH2N(CH3)2, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH 2SH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -OCH2NH2, -OCH2CH2NH2, -OCH2CH2CH2NH2, -OCH2SH, -OCH2CH2SH, -OCH2CH2CH2SH, -NHCH2OH, -NHCH2 CH2OH, -NHCH2CH2CH2OH, -NHCH2NH2, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2SH, -NHCH2CH2SH, -NHCH2CH2CH2SH, -N(CH3)CH2OH, -N(CH3)CH2CH 2OH, -N(CH3)CH2CH2CH2OH, -N(CH3)CH2NH2, -N(CH3)CH2CH2NH2, -N(CH3)CH2CH2CH2NH2, -N(CH3)CH2SH, -N(CH3)CH2CH2SH, -N(CH3)CH2CH2CH2SH 、 -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(COCH3)CH2NH2, -N(COCH3)CH2CH2NH2, -N(COCH3)CH2CH2CH2NH2, -N(COCH3)CH2SH, -N(COCH3)CH2C H2SH, -N(COCH3)CH2CH2CH2SH-N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH, -N(SO2CH3)CH2NH2, -N(SO2CH3)CH2CH2NH2, -N(SO2CH3)CH2CH2CH2NH 2、 -N(SO2CH3)CH2SH, -N(SO2CH3)CH2CH2SH, -N(SO2CH3)CH2CH2CH2SH.

[0130] Preferably, U is selected from the following groups:

[0131] In some embodiments, the -TUZ- together form a group selected from:

[0132] In some embodiments, the -TUZ- groups together form a group selected from the group consisting of C1-C6 alkylene; preferably, the -TUZ- groups together form a group selected from the group consisting of C1 alkylene, 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene, and 1,6-hexylene.

[0133] In some embodiments, Y is selected from the group consisting of a chemical bond, -C(=O)NH-, -C(=O)NHCH2-, -C(=O)NHCH2CH2-, -C(=O)NHCH2CH2CH2-, -NHC(=O)-, -NHC(=O)CH2-, -NHC(=O)CH2CH2-, -NHC(=O)CH2CH2-, -NHC(=O)CH2CH2CH2-, -O-, -OCH2-, -OCH2CH2-, -OCH2CH2CH2-, -NR2-, -NR2CH2-, -NR2CH2CH2-, -NR2CH2CH2CH2-.

[0134] In some embodiments, Y is selected from: a chemical bond, -NR 14 C(=O)-, -C(=O)NR 14 -, -C(=O)NR 14 CH2-, -C(=O)NHCHR9-, -NR 14 C(=O)CH2-, -NHC(=O)CHR9-, -O-, -OCHR9-, -OCHR9CH2-, -OCH2CHR9-, -NR2-, -NR2CH2-, -NHCHR9-.

[0135] Preferably, said R9 is selected from: hydrogen, C1-C4 alkyl, R 13 More preferably, the R9 is selected from: R 13 .

[0136] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n .

[0137] Preferably, the R 14 Selected from: R n 、-C(=O)R n .

[0138] Preferably, said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; more preferably, R2 is selected from the group consisting of: R 14 Among them, preferably, the R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n .

[0139] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0140] In some specific embodiments, said R9 is selected from: hydrogen, C1-C4 alkyl, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 ; the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ; the R 14 Selected from: R n 、-C(=O)R n ; said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl and -C(=O)C3-C 10The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9 selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; wherein R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0141] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0142] Therefore, preferably, the R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2O H, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -S(=O)2 CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH. In some embodiments, the R2 is further selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O) CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C(=O)O CH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、-C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH 2. -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S (=O)2CH2NH2, -S(=O)2CH2CH2NH2, -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O) 2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH 2、 -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

[0143] Preferably, the R 14 Selected from: R n 、-C(=O)R n .

[0144] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, R n Selected from: hydroxy substituted C1-C4 alkyl; most preferably, R n In some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0145] In some embodiments, L is selected from: -CH2-, -CH2CH2-, -C(=O)-, -CH(OH)-.

[0146] Preferably, L is selected from: -CH2-, -C(=O)-, and -CH(OH)-.

[0147] In some embodiments, said R3-R5 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl are optionally substituted by 1-3 groups selected from halogen, C1-C3 alkyl or C1-C3 alkoxy; when R3-R5 are multiple, any two adjacent groups can be combined to form a ring.

[0148] Preferably, said R3 is selected from: R 13 .

[0149] Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m More preferably, the R 13 Selected from: hydroxyl, R n 、-OR n .

[0150] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, R n Selected from: hydroxy substituted C1-C4 alkyl; most preferably, R n In some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, Rn Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0151] Preferably, R m Selected from: hydrogen, -C1-C4 alkyl.

[0152] Preferably, R4-R5 are independently selected from: hydrogen, halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl.

[0153] In some embodiments, the R6 is selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, the alkyl and cycloalkyl groups are optionally substituted by 1-3 groups selected from halogen, hydroxy, cyano, amino, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 、-C(=O)NHR 23 Or -OP(=O)(OM)2 group substitution.

[0154] In some embodiments, R6 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, -C1-C4 alkylene OC(=O)R 23 、-C1-C4 alkylene C(=O)OR 23 、-C1-C4 alkylene OP(=O)(OH)2;R 23 Selected from: hydrogen, C1-C4 alkyl, the C1-C4 alkyl is optionally substituted by 1-3 groups selected from hydroxyl and amino.

[0155] In some embodiments, R6 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, -CH2OC(=O)R 23 、-CH2CH2OC(=O)R 23 、-CH2C(=O)OR 23 、-CH2CH2C(=O)OR 23 , -CH2OP(=O)(OH)2, -CH2CH2OP(=O)(OH)2; R 23 Selected from: hydrogen, C1-C4 alkyl, the C1-C4 alkyl is optionally substituted by 1-3 groups selected from hydroxyl and amino.

[0156] In some embodiments, R6 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, -CH2OC(=O)C1-C4 alkyl, -CH2OC(=O)CH2OH, -CH2OC(=O)CH2NH2, and -CH2OP(=O)(OH)2.

[0157] In some embodiments, the R6 is selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, the alkyl, cycloalkyl is optionally substituted by 1-3 halogen, C1-C3 alkyl or C 1- The residue is substituted with a C3 alkoxy group.

[0158] Preferably, R6 is selected from the group consisting of hydrogen, C1-C4 alkyl, and C1-C4 haloalkyl.

[0159] In some embodiments, the compound is a compound represented by formula (I-1) or formula (I-2) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0160] Wherein, R1, R3-R6, Q, T, U, Z, Y, L, n, and m are as defined above.

[0161] In some embodiments, the compound is a compound represented by formula (II) or formula (III) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0162] Wherein, R1, R3-R6, Q, T, U, Z, Y, L, n, and m are as defined above.

[0163] In some embodiments, the compound is a compound represented by formula (IV) or formula (V) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0164] Among them, the R a CH2C(=O)NH-、-C(R 94 )(R 95 )NHC(=O)-、-C(R 94 )(R 95 )C(=O)NH-"NH" is optionally replaced by R 14 replace;

[0165] R a 、R 14 , L is defined as above;

[0166] R 91 -R 95are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; R 92 -R 94 Any two adjacent ones can combine to form a ring.

[0167] Preferably, the R 91 Selected from: hydrogen, R 13 , halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclic group containing 1-3 heteroatoms, the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclic group are optionally substituted by 1-3 groups selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; more preferably, the R 91 Selected from: hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2Rn 、-NR n -S(=O)2R m ; Also preferably, the R 91 Selected from: hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0168] Preferably, the R 92 -R 94 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 92 -R 94 Any two adjacent groups can combine to form a cycloalkyl group; more preferably, the R 92 -R 94 Each independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 92 With R 93 Together they form -CH2CH2-, or R 94 With R 95 Together they form -CH2CH2-.

[0169] In some embodiments, the R a CH2C(=O)NH-、-C(R 94 )(R 95 )NHC(=O)-、-C(R 94 )(R 95 )C(=O)NH- "NH" is unsubstituted.

[0170] In some embodiments, the R 91 Selected from R 13 , or R 91 -R 95 One of the R 13 .

[0171] The R 13 、R m 、R n Same definition as above.

[0172] In some embodiments, the compound is a compound represented by formula (IV') or formula (V') and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0173] Among them, R a 、R 91 Same definition as above.

[0174] In some embodiments, R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH. m In some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH.

[0175] In some embodiments, the compound is a compound represented by formula (VI) or formula (VII) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0176] Wherein, the "NH" in the -CH2C(=O)NH- is optionally replaced by R 14 replace;

[0177] R a , R2, R 91 、R 14, L is defined as above;

[0178] R 96 -R 99 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; R 96 -R 99 Any two adjacent ones can combine to form a ring.

[0179] Preferably, the R 96 -R 99 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 96 -R 99 Any two adjacent groups can combine to form a cycloalkyl group; more preferably, the R 96 -R 99 Each independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 96 With R 97 Together they form -CH2CH2-, or R 98 With R 99 Together they form -CH2CH2-.

[0180] Preferably, said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; more preferably, R2 is selected from the group consisting of: R 14 .

[0181] Preferably, the R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n .

[0182] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R n In some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0183] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0184] In some embodiments, R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2 OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -S(=O) 2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH. In some embodiments, the R2 is further selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2 OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)O CH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、-C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2S H, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2 , -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2 CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

[0185] Preferably, R2 is selected from: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2OH. In some embodiments, R2 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH 、-C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2C H2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、 -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2 CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH 。

[0186] In some embodiments, the "NH" in the -CH2C(=O)NH- is unsubstituted.

[0187] In some embodiments, the R2 is selected from R 14 , or the R 91 Selected from R 13 , or the R 96 -R 99 One of the R 13 .

[0188] The R 13 、R 14 、R m 、R n Same definition as above.

[0189] In some embodiments, the compound is a compound represented by formula (VI') or formula (VII') and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0190] Among them, R a , R2, R 91 Same definition as above.

[0191] In some embodiments, the R2 is selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n .

[0192] In some embodiments, the R 91 Selected from: hydroxyl, R n、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0193] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH. m Selected from: hydrogen, -C1-C4 alkyl.

[0194] In some embodiments, the compound is a compound represented by formula (VIII) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0195] Among them, R1, Q, R2, R 91 , L is defined as above;

[0196] R 100 -R 103 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; R96 -R 99 Any two adjacent ones can combine to form a ring.

[0197] Preferably, the R 100 -R 103 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 100 -R 103 Any two adjacent groups can combine to form a cycloalkyl group; more preferably, the R 100 -R 103 Each independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 100 With R 101 Together they form -CH2CH2-, or R 102 With R 103 Together they form -CH2CH2-.

[0198] Preferably, said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; more preferably, R2 is selected from the group consisting of: R 14 .

[0199] Preferably, the R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n .

[0200] Preferably, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; Most preferably, the R nIn some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0201] Preferably, the R m Selected from: hydrogen, -C1-C4 alkyl.

[0202] In some embodiments, R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2 OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -S(=O) 2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH. In some embodiments, the R2 is further selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH 、-C(=O)CH2OH、-C(=O)CH2CH2OH、-C(=O)CH2CH2CH2OH、-C(=O)CH2NH2、-C(=O)CH2CH2NH2、-C(=O)CH2CH2CH2NH2、-C(=O)CH2SH、-C(=O)CH2CH2SH、-C(=O)CH2CH2CH2SH、-C(=O)OCH2OH、-C(=O)OCH2CH2OH、-C(=O)OCH2CH2CH2OH、-C(=O)OCH2NH2、-C(=O)OCH2CH2NH2、-C(=O)OCH2CH2CH2NH2、-C(=O)OCH2SH、-C(=O)OCH2CH2SH、-C(=O)OCH2CH2CH2SH 、 -C(=O)NHCH2OH、-C(=O)NHCH2CH2OH、-C(=O)NHCH2CH2CH2OH、-C(=O)NHCH2NH2、-C(=O)NHCH2CH2NH2、-C(=O)NHCH2CH2CH2NH2、-C(=O)NHCH2SH、-C(=O)NHCH2CH2SH、-C(=O)NHCH2CH2CH2SH 、 -S(=O)2CH2OH、-S(=O)2CH2CH2OH、-S(=O)2CH2CH2CH2OH、-S(=O)2CH2NH2、-S(=O)2CH2CH2NH2、-S(=O)2CH2CH2CH2NH2、-S(=O)2CH2SH、-S(=O)2CH2CH2SH、-S(=O)2CH2CH2CH2SH、-S(=O)2NHCH2OH、-S(=O)2NHCH2CH2OH、-S(=O)2NHCH2CH2CH2OH、-S(=O)2NHCH2NH2、-S(=O)2NHCH2CH2NH2、-S(=O)2NHCH2CH2CH2NH2、-S(=O)2NHCH2SH、-S(=O)2NHCH2CH2SH、-S(=O)2NHCH2CH2CH2SH。

[0203] Preferably, R2 is selected from: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2OH. In some embodiments, R2 is further selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OC H2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C (=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH, -C(=O)NH CH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH.

[0204] In some embodiments, the R2 is selected from R 14 , or the R 91 Selected from R 13 , or the R 100 -R 103 One of the R 13 .

[0205] The R 13 、R 14 、Rm 、R n Same definition as above.

[0206] In some embodiments, the compound is a compound represented by formula (VIII') and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0207] Among them, R1, Q, R2, R 91 Same definition as above.

[0208] In some embodiments, the R2 is selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n .

[0209] In some embodiments, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0210] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH. m In some embodiments, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0211] In some embodiments, the compound is a compound represented by formula (XI) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0212] Wherein, the "NH" in the -C(=O)NHCH2- is optionally replaced by R 14 replace;

[0213] R a 、R 14 、R 91 , a2 is defined as above;

[0214] R 104 Selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy.

[0215] Preferably, the R 104 Selected from: hydrogen, R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl; More preferably, the R 104 Selected from: hydrogen, F, Cl, Br, methyl, ethyl, trifluoromethyl, hydroxyl, R n 、-OR n .

[0216] In some specific embodiments, the R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R nSelected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0217] In some specific embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0218] In some embodiments, the "NH" in the -C(=O)NHCH2- is unsubstituted.

[0219] In some embodiments, the R 91 Selected from R 13 , or the R 104 One of the R 13 .

[0220] The R 13 、R m 、R n Same definition as above.

[0221] In some embodiments, the compound is a compound represented by formula (XI') and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0222] Among them, R a 、R 91 、R 104 Same definition as above.

[0223] In some embodiments, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0224] In some embodiments, the R 104 Selected from: hydroxyl, R n 、-OR n .

[0225] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH. m In some embodiments, the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0226] In one embodiment, in the compound of formula (I) of the present invention and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0227] The R1 is selected from: a C(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-、R a CHR9CH2-、R a CHCHR9-; wherein R9 is selected from hydrogen, R 13 ; the R 13 Selected from: hydroxyl, thiol, amino, R n ; the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino;

[0228] R aSelected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazol-9-yl, 1-azacarbazol-9-yl, 2-azacarbazol-9-yl, 1,8-diazacarbazol-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazin-10-yl, fluoren-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin- 8-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5-(8-quinolin-yl)-pyridin-2-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl; or R a Selected from: 5-(1-isoquinolin-yl)-pyridin-2-yl;

[0229] R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl; the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; said R m Selected from: hydrogen, -C1-C4 alkyl;

[0230] Q is selected from: -NR2-,

[0231] Said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl; said R 14 Selected from: R n 、-C(=O)R n、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; the R n is selected from the group consisting of: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; said R m Selected from: hydrogen, -C1-C4 alkyl;

[0232] described Select one of the following structures:

[0233] wherein each R9 is independently selected from: hydrogen, R 13 ; the R 13 Selected from: hydroxyl, thiol, amino, R n ; the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino;

[0234] Each a1 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9; each a2 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8;

[0235] Said T and Z are independently selected from: chemical bond, methylene, 1,2-ethylene;

[0236] The U is selected from: C1-C6 alkylene, 1,4-phenylene, the 1,4-phenylene is optionally substituted by one or more R9; the R9 is selected from: hydrogen, amino, hydroxyl, thiol, R 13 ; the R 13 Selected from: R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、 -NR m -S(=O)2R n 、-NR n -S(=O)2Rm ; the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; said R m Selected from: hydrogen, -C1-C4 alkyl;

[0237] Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-NR2(CH2) b -;

[0238] L is selected from: -(CR7R8) o -, -C(=O)-; said R7-R8 are independently selected from: hydrogen;

[0239] The R3-R5 are independently selected from: hydrogen;

[0240] Said R6 is selected from: hydrogen;

[0241] b is selected from: 0, 1, 2, 3, 4 or 5;

[0242] n is selected from: 0, 1, 2 or 3;

[0243] m is selected from: 0, 1, 2, 3 or 4;

[0244] oSelected from: 1.

[0245] In one embodiment, in the compound of formula (I) of the present invention and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0246] The R1 is selected from: a C(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-、R a CHR9CH2-、R a CHCHR9-; wherein R9 is selected from hydrogen, R 13 ; the R 13 Selected from: hydroxyl, thiol, amino, R n ; the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino;

[0247] The R a Selected from the following groups:

[0248] or

[0249] Q is selected from: -NR2-,

[0250] Said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl; said R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、 -S(=O)2NR m R n ; the R n is selected from the group consisting of: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; said R m Selected from: hydrogen, -C1-C4 alkyl;

[0251] described Select one of the following structures:

[0252] wherein each R9 is independently selected from: hydrogen, R 13 ; the R 13 Selected from: hydroxyl, thiol, amino, R n ; the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino;

[0253] Each a1 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9; each a2 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8;

[0254] Said T and Z are independently selected from: chemical bond, methylene, 1,2-ethylene;

[0255] The U is selected from: C1-C6 alkylene, 1,4-phenylene, the 1,4-phenylene is optionally substituted by one or more R9; the R9 is selected from: hydrogen, amino, hydroxyl, thiol, R 13 ; the R 13 Selected from: R n 、-OR n 、-OC(=O)R n、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; said R m Selected from: hydrogen, -C1-C4 alkyl;

[0256] Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-NR2(CH2) b -;

[0257] L is selected from: -(CR7R8) o -, -C(=O)-; said R7-R8 are independently selected from: hydrogen;

[0258] The R3-R5 are independently selected from: hydrogen;

[0259] Said R6 is selected from: hydrogen;

[0260] b is selected from: 0, 1, 2, 3, 4 or 5;

[0261] n is selected from: 0, 1, 2 or 3;

[0262] m is selected from: 0, 1, 2, 3 or 4;

[0263] oSelected from: 1.

[0264] In some particular embodiments, the present invention protects:

[0265] Item 1. Compounds represented by formula (I) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof:

[0266] in,

[0267] R1 is selected from: a (CH2) a -、R a (CH2) a C(=O)-、R a (CH2) a NHC(=O)-、R a (CH2)a OC(=O)- or R a (CH2) a S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace;

[0268] Q is selected from: -NR2-, -O-,

[0269] R2 is selected from: hydrogen, R b -、R b C(=O)-、R b S(=O)2-、R 14 ;

[0270] Ring A represents a heterocycloalkyl group containing at least one N atom as a heteroatom, which is connected to T via the N atom, and Ring A is optionally substituted by one or more groups selected from R9;

[0271] R a 、R b Selected from: C1-C8 alkyl, C3-C 10 Cycloalkyl, C3-C 10 Bridged ring group, -NR 11 R 12 、C3-C 10 Any containing O, S, SO2, N or NHC(=O)R 22 The C1-C8 alkyl group may be a heterocyclic group, an aryl group, a heteroaryl group, a fused arylcycloalkyl group, a fused arylheterocyclic group, a fused heteroarylcycloalkyl group, a fused heteroarylheterocyclic group, an aryl-alkyl group, a heteroaryl-alkyl group, an aryl-cycloalkyl group, an aryl-heterocyclic group, a cycloalkyl-heterocyclic group, a heterocyclic group-heterocyclic group, and any two CC groups in the C1-C8 alkyl group may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and R a Optionally substituted with one or more R9, R b Optionally one or more R 10 replace;

[0272] T, U, and Z are independently selected from the group consisting of: chemical bonds, carbonyl groups, C1-C6 alkylene groups, C3-C 10 Cycloalkylene, arylene, heteroarylene, heterocyclylene, wherein the alkylene, cycloalkylene, arylene, heteroarylene, heterocyclylene is optionally substituted by one or more R9;

[0273] Y is selected from: chemical bond, -C(=O)NH(CH2) b-, -NHC(=O)(CH2) b -、-O(CH2) b -、-NR2(CH2) b -, the "CH2" is optionally substituted by one or more R9, or is optionally substituted by -CH2CH2-, the "NH" is optionally substituted by R 14 replace;

[0274] L is selected from: -(CR7R8) o -, -C(=O)-;

[0275] R3-R5, R7-R9 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R3-R5, R7-R9 are multiple, any two adjacent groups may be combined to form a ring;

[0276] R 10 Selected from: hydrogen, halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R 10 In the case of multiple, any two adjacent ones can combine to form a ring;

[0277] R 13 Selected from: hydroxyl, R n 、-OR n 、-C(=O)R n 、-C(=O)OR n 、-OC(=O)R n 、-NR m R n 、-C(=O)NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-S(=O)2R n 、-S(=O)2NR m R n 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0278] R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0279] R nSelected from: C1-C8 alkyl substituted by hydroxy, wherein any two CCs in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted with 1-3 groups selected from halogen, cyano, amino, nitro, or C1-C3 alkoxy;

[0280] R m Independently selected from: hydrogen, C1-C8 alkyl, any two CC in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted with 1-3 groups selected from halogen, hydroxy, cyano, amino, nitro, or C1-C3 alkoxy;

[0281] R6 is selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted by 1-3 halogen, hydroxyl, cyano, amino, nitro, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 、-C(=O)NHR 23 , C1-C3 alkyl, C 1- C3 alkoxy or -OP(=O)(OM)2 group substitution;

[0282] M is independently selected from: hydrogen, C1-C4 alkyl;

[0283] R 11 、R 12 Each is independently selected from: hydrogen, C1-C4 alkyl, aryl, aryl-alkyl;

[0284] R 21 Selected from: chemical bonds, C1-C4 alkylene;

[0285] R 22 、R 23 Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, aryl, and aryl-alkyl, wherein the C1-C4 alkyl, aryl, and aryl-alkyl are optionally substituted by a group selected from halogen, hydroxy, and amino;

[0286] a is selected from: 0, 1, 2, 3, 4 or 5;

[0287] b is selected from: 0, 1, 2, 3, 4 or 5;

[0288] n is selected from: 0, 1, 2 or 3;

[0289] m is selected from: 0, 1, 2, 3 or 4;

[0290] o Select from: 1 or 2;

[0291] Wherein, the compound represented by formula (I) contains at least one selected from R 13 or R 14 Groups;

[0292] Provided that the compound is not:

[0293] Item 2. Compounds represented by formula (I) and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof:

[0294] in,

[0295] R1 is selected from: a (CH2) a -、R a (CH2) a C(=O)-、R a (CH2) a NHC(=O)-、R a (CH2) a OC(=O)- or R a (CH2) a S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace;

[0296] Q is selected from: -NR2-, -O-,

[0297] R2 is selected from: hydrogen, R b -、R b C(=O)-、R b S(=O)2-、R 14 ;

[0298] Ring A represents a heterocycloalkyl group containing at least one N atom as a heteroatom, which is connected to T or R1 through the N atom, and Ring A is optionally substituted by one or more groups selected from R9;

[0299] R a 、R b Selected from: C1-C8 alkyl, C3-C 10 Cycloalkyl, C3-C 10 Bridged ring group, -NR 11 R 12 、C3-C 10 Any containing O, S, SO2, N or NHC(=O)R 22 wherein the C1-C8 alkyl group is a heterocyclic group, an aryl group, a heteroaryl group, a fused arylcycloalkyl group, a fused arylheterocyclic group, a fused heteroarylcycloalkyl group, a fused heteroarylheterocyclic group, an aryl-aryl group, an aryl-heteroaryl group, a heteroaryl-aryl group, a heteroaryl-heteroaryl group, an aryl-alkyl group, a heteroaryl-alkyl group, an aryl-cycloalkyl group, an aryl-heterocyclic group, a cycloalkyl-heterocyclic group, a heterocyclic group-heterocyclic group, and any two CC groups in the C1-C8 alkyl group may be inserted with a group selected from the group consisting of -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, -NHS(=O)2-, and R a Optionally substituted with one or more R9, R b Optionally one or more R 10 replace;

[0300] T, U, and Z are independently selected from the group consisting of: chemical bonds, N, O, carbonyl, C1-C6 alkylene, C3-C 10 Cycloalkylene, arylene, heteroarylene, heterocyclylene, wherein the alkylene, cycloalkylene, arylene, heteroarylene, heterocyclylene is optionally substituted by one or more R9;

[0301] Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-O(CH2) b -、-NR2(CH2) b -, the "CH2" is optionally substituted by one or more R9, or is optionally substituted by -CH2CH2-, the "NH" is optionally substituted by R 14 replace;

[0302] L is selected from: -(CR7R8) o -, -C(=O)-;

[0303] R3-R5, R7-R9 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, hydroxyl, thiol, nitro, -R 21 N(R 22 )R 22 、-R 21 C(=O)R22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R3-R5, R7-R9 are multiple, any two adjacent groups may be combined to form a ring;

[0304] R 10 Selected from: hydrogen, halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; when R 10 In the case of multiple, any two adjacent ones can combine to form a ring;

[0305] R13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-C(=O)R n 、-C(=O)OR n 、-OC(=O)R n 、-NR m R n 、-C(=O)NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-S(=O)2R n 、-S(=O)2NR m R n 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0306] R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0307] R n Selected from: C1-C8 alkyl substituted by hydroxy, thiol or amino, wherein any two CCs in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted by 1-3 groups selected from halogen, cyano, amino, nitro or C1-C3 alkoxy;

[0308] R mIndependently selected from: hydrogen, C1-C8 alkyl, any two CC in the C1-C8 alkyl may be inserted with a group selected from one of -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, and -NHS(=O)2-, and the C1-C8 alkyl is optionally substituted with 1-3 groups selected from halogen, hydroxy, cyano, amino, nitro, or C1-C3 alkoxy;

[0309] R6 is selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted by 1-3 halogen, hydroxyl, cyano, amino, nitro, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 、-C(=O)NHR 23 , C1-C3 alkyl, C 1- C3 alkoxy or -OP(=O)(OM)2 group substitution;

[0310] M is independently selected from: hydrogen, C1-C4 alkyl;

[0311] R 11 、R 12 Each is independently selected from: hydrogen, C1-C4 alkyl, aryl, aryl-alkyl;

[0312] R 21 Selected from: chemical bonds, C1-C4 alkylene;

[0313] R 22 、R 23 Each is independently selected from the group consisting of hydrogen, C1-C4 alkyl, aryl, and aryl-alkyl, wherein the C1-C4 alkyl, aryl, and aryl-alkyl are optionally substituted by a group selected from halogen, hydroxy, and amino;

[0314] a is selected from: 0, 1, 2, 3, 4 or 5;

[0315] b is selected from: 0, 1, 2, 3, 4 or 5;

[0316] n is selected from: 0, 1, 2 or 3;

[0317] m is selected from: 0, 1, 2, 3 or 4;

[0318] o Select from: 1 or 2;

[0319] The compound represented by the formula (I) is not:

[0320] Preferably, the compound represented by formula (I) contains at least one selected from R 13 or R 14 group.

[0321] Item 3. The compound of Item 1 or 2 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that R1 is selected from: R a C(=O)-、R a CH2C(=O)-、R a CH2CH2C(=O)-、R a -、R a CH2-、R a CH2CH2-、R a NHC(=O)-、R a CH2NHC(=O)-、R a CH2CH2NHC(=O)-、R a OC(=O)-、R a CH2OC(=O)-、R a CH2CH2OC(=O)-、R a S(=O)2-、R a CH2S(=O)2-、R a CH2CH2S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace.

[0322] Item 4. The compound of Item 3 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R1 is selected from: R a C(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-、R a CHR9CH2-、R a CHCHR9-、R a NR 14 C(=O)-、R a CHR9NHC(=O)-、R a CHNR 14 C(=O)-、R aCHR9CH2NHC(=O)-、R a CH2CHR9NHC(=O)-、R a CH2CH2NR 14 C(=O)-、R a OC(=O)-、R a CHR9OC(=O)-、R a CHR9CH2OC(=O)-、R a CH2CHR9OC(=O)-、R a CHR9S(=O)2-、R a CHR9CH2S(=O)2-、R a CH2CHR9S(=O)2-.

[0323] Item 5. The compound according to Item 3 or 4, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0324] Said R9 is selected from: hydrogen, C1-C4 alkyl, R 13 ;

[0325] The R 13 Selected from: hydroxyl, R n 、-OR n ;

[0326] The R 14 Selected from: R n 、-C(=O)R n ;

[0327] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0328] Item 6. The compound according to Item 3 or 4, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0329] Said R9 is selected from: hydrogen, C1-C4 alkyl, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 ;

[0330] The R 13Selected from: hydroxyl, thiol, amino, R n 、-OR n ;

[0331] The R 14 Selected from: R n 、-C(=O)R n ;

[0332] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0333] Item 7. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R a is selected from the group consisting of phenyl, naphthyl, carbazolyl, 1-azacarbazolyl, 2-azacarbazolyl, 1,8-diazacarbazolyl, indolyl, 7-azaindolyl, 2,3-dihydroindolyl, 2,3-dihydro-7-azaindolyl, phenoxazinyl, fluorenyl, quinolyl, isoquinolyl, naphthyridinyl, tetrahydronaphthyridinyl, tetrahydroquinolyl, pyrimidinyl, triazolyl, bicyclo[1.1.1]pentanyl, norbornyl, and adamantyl; preferably, the R a Optionally substituted with one or more R9 selected from hydrogen, R 13 , halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

[0334] Item 8. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R a is selected from the group consisting of: phenyl, naphthyl, carbazolyl, 1-azacarbazolyl, 2-azacarbazolyl, 1,8-diazacarbazolyl, indolyl, 7-azaindolyl, 2,3-dihydroindolyl, 2,3-dihydro-7-azaindolyl, phenoxazinyl, fluorenyl, quinolyl, isoquinolyl, naphthyridinyl, tetrahydronaphthyridinyl, tetrahydroquinolyl, pyrimidinyl, pyridyl, quinolyl-pyridyl, triazolyl, bicyclo[1.1.1]pentanyl, norbornyl, and adamantyl; preferably, the R aOptionally substituted with one or more R9 selected from hydrogen, R 13 , halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

[0335] Item 9. The compound according to Item 7 or 8, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R a Selected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazol-9-yl, 1-azacarbazol-9-yl, 2-azacarbazol-9-yl, 1,8-diazacarbazol-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazin-10-yl, fluoren-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-1-yl, quinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl; preferably, R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl.

[0336] Item 10. The compound according to Item 7 or 8, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R aSelected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazol-9-yl, 1-azacarbazol-9-yl, 2-azacarbazol-9-yl, 1,8-diazacarbazol-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazin-10-yl, fluoren-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl -yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5-(8-quinolin-yl)-pyridin-2-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl; preferably, R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl.

[0337] Item 11. The compound according to any one of Items 7 to 10, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0338] The R 13 Selected from: hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ;

[0339] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0340] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0341] Item 12. The compound according to any one of Items 7 to 10, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0342] The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ;

[0343] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R nSelected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH;

[0344] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0345] Item 13. The compound according to Item 11 or 12, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, It is characterized in that R9 is selected from: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -NHCH2OH, -NHCH2CH2OH, -NHCH2CH2OH, -NHCH2CH2OH, -N(CH3)CH2OH, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2CH2OH, -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH.

[0346] Item 14. The compound according to Item 11 or 12, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs, wherein R9 is selected from the group consisting of: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, thiol, amino, -C(=O)CH3, C(=O)CH2CH 3、 C(=O)CH2CH2CH 3、-CH2CH2N(CH3)2, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH 2SH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -OCH2NH2, -OCH2CH2NH2, -OCH2CH2CH2NH2, -OCH2SH, -OCH2CH2SH, -OCH2CH2CH2SH, -NHCH2OH, -NHCH2 CH2OH, -NHCH2CH2CH2OH, -NHCH2NH2, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2SH, -NHCH2CH2SH, -NHCH2CH2CH2SH, -N(CH3)CH2OH, -N(CH3)CH2CH 2OH, -N(CH3)CH2CH2CH2OH, -N(CH3)CH2NH2, -N(CH3)CH2CH2NH2, -N(CH3)CH2CH2CH2NH2, -N(CH3)CH2SH, -N(CH3)CH2CH2SH, -N(CH3)CH2CH2CH2SH 、 -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(COCH3)CH2NH2, -N(COCH3)CH2CH2NH2, -N(COCH3)CH2CH2CH2NH2, -N(COCH3)CH2SH, -N(COCH3)CH2C H2SH, -N(COCH3)CH2CH2CH2SH-N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH, -N(SO2CH3)CH2NH2, -N(SO2CH3)CH2CH2NH2, -N(SO2CH3)CH2CH2CH2NH 2、 -N(SO2CH3)CH2SH, -N(SO2CH3)CH2CH2SH, -N(SO2CH3)CH2CH2CH2SH.

[0347] Item 15. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R a Selected from the following groups:

[0348] Item 16. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R a Selected from the following groups:

[0349] Item 17. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy or aryl; preferably, R2 is selected from the group consisting of R 14 .

[0350] Item 18. The compound according to Item 17, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0351] The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0352] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0353] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0354] Item 19. The compound according to Item 17, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0355] The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0356] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH;

[0357] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0358] Item 20. The compound according to Item 18 or 19 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2OH, )CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2C H2OH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH.

[0359] Item 21. The compound according to Item 18 or 19, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2 , -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C(=O)OCH2CH 2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(= O)OCH2CH2CH2SH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)N HCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2 CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2, -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S (=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH 2、-S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

[0360] Item 22. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the Select one of the following structures:

[0361] wherein each R9 is independently selected from: hydrogen, R 13 , halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy;

[0362] Each a1 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, each a2 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, each a3 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, each a4 is independently selected from: 0, 1, 2, 3, 4, 5, 6, each a5 is independently selected from: 0, 1, 2, 3, 4, 5.

[0363] Item 23. The compound according to Item 22, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0364] The R 13 Selected from: hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0365] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0366] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0367] Item 24. The compound according to Item 22, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0368] The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0369] The R n Selected from: the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2 or -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH;

[0370] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0371] Item 25. The compound according to Item 22 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the Select one of the following structures:

[0372] Item 26. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that T and Z are independently selected from: a chemical bond, a carbonyl group, a C1-C6 alkylene group or a C3-C 10 Cycloalkylene, the C1-C6 alkylene, C3-C 10The cycloalkylene group is optionally substituted with one or more R9.

[0373] Item 27. The compound according to Item 26 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that T and Z are independently selected from: a chemical bond, a carbonyl group, a methylene group, a 1,2-ethylene group, a 1,1-cyclopropylene group or a 2,2-propylene group, and the methylene group, the 1,2-ethylene group, the 1,1-cyclopropylene group is optionally substituted by one or more R9.

[0374] Item 28. The compound according to Item 26 or 27, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0375] Said R9 is selected from: hydrogen, R 13 , C1-C6 alkyl or C3-C8 cycloalkyl;

[0376] The R 13 Selected from: hydroxyl, R n 、-OR n ;

[0377] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0378] Item 29. The compound according to Item 26 or 27, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0379] The R9 is selected from: hydrogen, hydroxyl, thiol, amino, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 , C1-C6 alkyl or C3-C8 cycloalkyl;

[0380] The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ;

[0381] The R n Selected from: the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R nSelected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0382] Item 30. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that U is selected from: C1-C6 alkylene, C3-C 10 Cycloalkylene, arylene or heteroarylene, wherein the alkylene, cycloalkylene, arylene or heteroarylene is optionally substituted by one or more R9; preferably, U is selected from: C2-C6 alkylene, C5-C6 cycloalkylene, C6-C 10 Arylene, 5-6 membered monocyclic heteroarylene, said alkylene, cycloalkylene, arylene, heteroarylene are optionally substituted by one or more R9.

[0383] Item 31. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that U is selected from: 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,3-cyclopentylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,5-pyridine The 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,3-cyclopentylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,5-pyridylene, 2,5-pyrimidylene, 2,5-thiazolylene, 2,4-oxazolylene is optionally substituted with one or more R9.

[0384] Item 32. The compound according to Item 30 or 31, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0385] Said R9 is selected from: hydrogen, R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy;

[0386] The R 13 Selected from: hydroxyl, R n 、-ORn 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0387] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0388] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0389] Item 33. The compound according to Item 30 or 31, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that:

[0390] The R9 is selected from: hydrogen, amino, hydroxyl, thiol, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy;

[0391] The R 13 Selected from: hydroxyl, amino, thiol, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ;

[0392] The Rn Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH;

[0393] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0394] Item 34. The compound according to Item 32 or 33, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R9 is selected from: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -NHCH2OH, -NHCH2CH2O H, -NHCH2CH2CH2OH, -N(CH3)CH2OH, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2CH2OH, -N(COCH3)CH2OH, -N(COCH3 )CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH.

[0395] Item 35. The compound according to Item 32 or 33, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, wherein R9 is selected from the group consisting of: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, thiol, amino, -COCH3, COCH2CH 3、 COCH2CH2CH 3、-CH2CH2N(CH3)2, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH 2SH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -OCH2NH2, -OCH2CH2NH2, -OCH2CH2CH2NH2, -OCH2SH, -OCH2CH2SH, -OCH2CH2CH2SH, -NHCH2OH, -NHCH2 CH2OH, -NHCH2CH2CH2OH, -NHCH2NH2, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2SH, -NHCH2CH2SH, -NHCH2CH2CH2SH, -N(CH3)CH2OH, -N(CH3)CH2CH 2OH, -N(CH3)CH2CH2CH2OH, -N(CH3)CH2NH2, -N(CH3)CH2CH2NH2, -N(CH3)CH2CH2CH2NH2, -N(CH3)CH2SH, -N(CH3)CH2CH2SH, -N(CH3)CH2CH2CH2SH 、 -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(COCH3)CH2NH2, -N(COCH3)CH2CH 2NH2, -N(COCH3)CH2CH2CH2NH2, -N(COCH3)CH2SH, -N(COCH3)CH2CH2SH, -N(COCH3)CH2CH2CH2SH-N(SO 2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH, -N(SO2CH3)CH2NH2, -N(SO2CH3)CH2CH 2NH2, -N(SO2CH3)CH2CH2CH2NH2, -N(SO2CH3)CH2SH, -N(SO2CH3)CH2CH2SH, -N(SO2CH3)CH2CH2CH2SH.

[0396] Item 36. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that U is selected from the following groups:

[0397] Item 37. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the -TUZ- together form a group selected from the group consisting of:

[0398] Item 38. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that Y is selected from: a chemical bond, -NR 14 C(=O)-, -C(=O)NR 14 -, -C(=O)NR 14 CH2-, -C(=O)NHCHR9-, -NR 14 C(=O)CH2-, -NHC(=O)CHR9-, -O-, -OCHR9-, -OCHR9CH2-, -OCH2CHR9-, -NR2-, -NR2CH2-, -NHCHR9-;

[0399] Said R9 is selected from: hydrogen, C1-C4 alkyl, R 13 ;

[0400] The R 13 Selected from: hydroxyl, R n 、-OR n ;

[0401] The R 14 Selected from: R n 、-C(=O)R n ;

[0402] Said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; wherein the R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2Rn 、-S(=O)2NR m R n ;

[0403] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0404] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0405] Item 39. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that Y is selected from: a chemical bond, -NR 14 C(=O)-, -C(=O)NR 14 -, -C(=O)NR 14 CH2-, -C(=O)NHCHR9-, -NR 14 C(=O)CH2-, -NHC(=O)CHR9-, -O-, -OCHR9-, -OCHR9CH2-, -OCH2CHR9-, -NR2-, -NR2CH2-, -NHCHR9-;

[0406] Said R9 is selected from: hydrogen, C1-C4 alkyl, -R 21 N(R 22 )R 22 、-R 21 C(=O)R 22 、R 13 ;

[0407] The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ;

[0408] The R 14 Selected from: R n 、-C(=O)R n ;

[0409] Said R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C10 Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl group is optionally substituted with one or more R9, wherein R9 is selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl; wherein the R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0410] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH;

[0411] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0412] Item 40. The compound according to Item 38 or 39 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2OH, )CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2C H2OH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH.

[0413] Item 41. The compound according to Item 38 or 39 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH 、 -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)OCH2OH, -C(=O)OCH2CH2 OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、-C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2 CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH 、 -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2 , -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NH CH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH 2. -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

[0414] Item 42. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that L is selected from: -CH2-, -CH2CH2-, -C(=O)-, -C(OH)-.

[0415] Item 43. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, wherein R3-R5 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl are optionally substituted by 1-3 groups selected from halogen, C1-C3 alkyl or C1-C3 alkoxy; when R3-R5 are multiple, any two adjacent groups can be combined to form a ring.

[0416] Item 44. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R6 is selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, and the alkyl and cycloalkyl groups are optionally substituted by 1-3 groups selected from halogen, hydroxyl, cyano, amino, -C(=O)OR23 、-OC(=O)R 23 、-NHC(=O)R 23 、-C(=O)NHR 23 Or -OP(=O)(OM)2 group substitution; preferably, the R6 is selected from: hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, -C1-C4 alkylene OC(=O)R 23 、-C1-C4 alkylene C(=O)OR 23 、-C1-C4 alkylene OP(=O)(OH)2;R 23 Selected from: hydrogen, C1-C4 alkyl, the C1-C4 alkyl is optionally substituted by 1-3 groups selected from hydroxyl and amino.

[0417] Item 45. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (I-1) or Formula (I-2):

[0418] Wherein, R1, R3-R6, Q, T, U, Z, Y, L, n, and m are as defined above.

[0419] Item 46. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (II) or Formula (III):

[0420] Wherein, R1, R3-R6, Q, T, U, Z, Y, L, n, and m are as defined above.

[0421] Item 47. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (IV) or Formula (V):

[0422] Among them, the R a CH2C(=O)NH-、-C(R 94 )(R 95 )NHC(=O)-、-C(R 94 )(R 95 )C(=O)NH-"NH" is optionally replaced by R 14 replace;

[0423] R a 、R 14 , L is defined as above;

[0424] R91 -R 95 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; R 92 -R 94 Any two adjacent ones can combine to form a ring.

[0425] Item 48. The compound according to Item 47, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R 91 Selected from: hydrogen, R 13 , halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclic group containing 1-3 heteroatoms, the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclic group are optionally substituted by 1-3 groups selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; preferably, the R 91 Selected from: hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)Rn 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m More preferably, the R 91 Selected from: hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ;

[0426] The R 92 -R 94 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 92 -R 94 Any two adjacent ones of can combine to form a cycloalkyl group; preferably, the R 92 -R 94 Each independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 92 With R 93 Together they form -CH2CH2-, or R 94 With R 95 Together they form -CH2CH2-.

[0427] Item 49. The compound according to Item 47 or 48, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R 91 Selected from R 13 , or R 91 -R 95 One of the R 13 .

[0428] Item 50. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (IV') or Formula (V'):

[0429] Among them, R a 、R 91 Same definition as above;

[0430] Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0431] Item 51. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (VI) or Formula (VII):

[0432] Wherein, the "NH" in the -CH2C(=O)NH- is optionally replaced by R 14 replace;

[0433] R a , R2, R 91 、R 14 , L is defined as above;

[0434] R 96 -R 99 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; R 96 -R 99Any two adjacent ones can combine to form a ring;

[0435] Preferably, the R 96 -R 99 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 96 -R 99 Any two adjacent groups can combine to form a cycloalkyl group; more preferably, the R 96 -R 99 Each independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 96 With R 97 Together they form -CH2CH2-, or R 98 With R 99 Together they form -CH2CH2-.

[0436] Item 52. The compound according to Item 51 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl is optionally substituted with one or more R9 selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl;

[0437] The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0438] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R nSelected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0439] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0440] Item 53. The compound according to Item 51 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl is optionally substituted with one or more R9 selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl;

[0441] The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0442] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH;

[0443] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0444] Item 54. The compound according to Item 52 or 53 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH 2CH2CH2OH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2OH; Preferably, R2 is selected from: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH , -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)O CH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH.

[0445] Item 55. The compound according to Item 52 or 53 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH 、-C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)OCH2OH, -C(=O)OCH2CH2 OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、 -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2 CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH 、 -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2 , -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NH CH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH 2. -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

[0446] Item 56. The compound according to any one of Items 51-55 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that R2 is selected from R 14 , or the R 91 Selected from R 13 , or the R 96 -R 99 One of the R 13 .

[0447] Item 57. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (VI') or Formula (VII'):

[0448] Among them, R a , R2, R 91 Same definition as above;

[0449] Preferably, said R2 is selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n ;

[0450] Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0451] Item 58. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by formula (VIII):

[0452] Among them, R1, Q, R2, R 91 , L is defined as above;

[0453] R 100 -R 103 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy; R 96 -R 99 Any two adjacent ones can combine to form a ring;

[0454] Preferably, the R 100 -R 103 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 100 -R 103 Any two adjacent groups can combine to form a cycloalkyl group; more preferably, the R 100 -R 103 Each independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 100 With R 101 Together they form -CH2CH2-, or R 102 With R 103 Together they form -CH2CH2-.

[0455] Item 59. The compound according to Item 58 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl is optionally substituted with one or more R9 selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl;

[0456] The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NRm R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0457] The R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH;

[0458] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0459] Item 60. The compound according to Item 58 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl, the C1-C8 alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of cycloalkyl, -C(=O)C1-C8 alkyl, or -S(=O)2C1-C8 alkyl is optionally substituted with one or more R9 selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy, or aryl;

[0460] The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ;

[0461] The R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R nSelected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH;

[0462] The R m Selected from: hydrogen, -C1-C4 alkyl.

[0463] Item 61. The compound according to Item 59 or 60, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)NHC H2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2NHCH2OH, -S(=O)2NHCH 2CH2OH, -S(=O)2NHCH2CH2CH2OH; Preferably, R2 is selected from: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2OH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2OH.

[0464] Item 62. The compound according to Item 59 or 60 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs, characterized in that R2 is selected from: hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2 OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、 -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH 2. -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S (=O)2CH2NH2, -S(=O)2CH2CH2NH2, -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O) 2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH 2、-S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH; Preferably, R2 is selected from: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, - C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2,, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C(=O)OCH2CH2 OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH 、 -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2C H2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH.

[0465] Item 63. The compound according to any one of Items 58-62 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that R2 is selected from R 14 , or the R 91 Selected from R 13 , or the R 100 -R 103 One of the R 13 .

[0466] Item 64. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by formula (VIII'):

[0467] Among them, R1, Q, R2, R91 Same definition as above;

[0468] Preferably, said R2 is selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n ;

[0469] Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

[0470] Item 65. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by formula (XI):

[0471] Wherein, the "NH" in the -C(=O)NHCH2- is optionally replaced by R 14 replace;

[0472] R a 、R 14 、R 91 , a2 is defined as above;

[0473] R 104 Selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 、-R 21 NHC(=O)R 22 、-R 21 C(=O)NHR 22 、-R 21 C(=O)OR 22 、-R 21 OC(=O)R 22 、-R 21 S(=O)2R 22 、-R 21 S(=O)2NHR 22, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl, or C1-C3 alkoxy;

[0474] Preferably, the R 104 Selected from: hydrogen, R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl; More preferably, the R 104 Selected from: hydrogen, F, Cl, Br, methyl, ethyl, trifluoromethyl, hydroxyl, R n 、-OR n .

[0475] Item 66. The compound according to Item 65 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R n Selected from: C1-C8 alkyl substituted with hydroxyl; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH or -CH2CH2CH2CH2OH.

[0476] Item 67. The compound according to Item 65 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted by hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

[0477] Item 68. The compound according to any one of Items 65-67 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that the R 91 Selected from R 13, or the R 104 One of the R 13 .

[0478] Item 69. The compound according to Item 1 or 2, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs thereof, characterized in that the compound is a compound represented by Formula (XI'):

[0479] Among them, R a 、R 91 、R 104 Same definition as above;

[0480] Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ;

[0481] Preferably, the R 104 Selected from: hydroxyl, R n 、-OR n .

[0482] The term "pharmaceutically acceptable salt" is used to describe a salt form of one or more compounds described herein, which is provided to increase the solubility of the compound in the gastric juices of the patient's gastrointestinal tract in order to promote dissolution and bioavailability of the compound. Pharmaceutically acceptable salts include, where applicable, salts derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include salts derived from alkali metals (e.g., potassium and sodium), alkaline earth metals (e.g., calcium, magnesium, and ammonium salts), as well as many other acids and bases well known in the pharmaceutical art.

[0483] The pharmaceutically acceptable salts of the present invention include hydrochloride, phosphate, hydrogen phosphate, dihydrogen phosphate, sulfate, nitrate, bicarbonate, carbonate, glutarate, hydrobromide, acetate, citrate, lactate, maleate, benzoate, methanesulfonate, oxalate, benzenesulfonate, p-toluenesulfonate, tartaric acid, malate, succinate, ascorbate, gluconate, lactate, and the like.

[0484] The term "solvate" is selected from the group consisting of hemihydrate, monohydrate, dihydrate, etc.; the term "stereoisomer" is selected from the group consisting of enantiomers or diastereomers, etc.; the term "prodrug" is a derivative of a compound that contains an additional moiety that is readily removed in vivo to produce the parent molecule as the pharmacologically active substance. One example of a prodrug is an ester, which is cleaved in vivo to produce the desired compound. Another example is an N-methyl derivative of a compound that is susceptible to oxidative metabolic mechanisms leading to N-demethylation. Prodrugs of various compounds, as well as materials and methods for deriving parent compounds to produce prodrugs, are known and can be adapted for use in the present invention.

[0485] The present invention specifically provides the following compounds:

[0486] Preferably, the present invention provides the following compounds:

[0487] Another object of the present invention is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the above-mentioned compound and its pharmaceutically acceptable salts, solvent compounds, stereoisomers, isotopes and prodrugs; the pharmaceutical composition may further comprise a MYC inhibitor, a DNA methyltransferase inhibitor or a Bcl-2 selective inhibitor; the MYC inhibitor is any one or more of OMO-103, APTO-253, PLX-51107, DCR-M1711, Oncomyc-NG, INX-3280, PU-27, GSK-3179106, cholesterol butyrate and NSC-165563; the DNA methyltransferase inhibitor is any one or more of 5-azacytidine, RG108, SGI-1027, GSK3685032, CM272, Bobcat339 hydrochloride, Decitabine (NSC 127716), Thioguanine (NSC 752), 2'-Deoxy-5-Fluorocytidine, Procainamide HCl or Zebularine (NSC 309132) any one or more; the Bcl-2 selective inhibitor is Venetoclax (ABT-199),

[0488] Any one or more of S55746, BDA-366, Obatoclax Mesylate (GX15-070), HA14-1, or APG-2575 (CAS No. 2180923-05-9). More preferably, the pharmaceutical composition comprises a Bcl-2 selective inhibitor, wherein the Bcl-2 selective inhibitor is venetoclax (ABT-199), Obatoclax Mesylate (GX15-070), or APG-2575 (CAS No. 2180923-05-9).

[0489] Another object of the present invention is to provide the use of the compounds of the present invention and their pharmaceutically acceptable salts, solvates, stereoisomers, isotope prodrugs, and pharmaceutical compositions in the preparation of protein degraders for any one or at least two of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR, and AR-V7.

[0490] Another object of the present invention is to provide the use of the compounds of the present invention and their pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs, and pharmaceutical compositions in the preparation of drugs for treating diseases associated with protein disorders of any one or at least two or more of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR, and AR-V7.

[0491] Another object of the present invention is to provide the use of the compounds of the present invention and their pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs, and pharmaceutical compositions in the treatment of diseases associated with protein disorders of any one or at least two or more of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR, and AR-V7.

[0492] Another object of the present invention is to provide a method for treating diseases related to protein disorder of any one or at least two or more of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7, which comprises administering to a subject in need thereof a therapeutically effective amount of the compound of the invention and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs and pharmaceutical compositions.

[0493] Another object of the present invention is to provide the compounds of the present invention and their pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs and pharmaceutical compositions, which are used to treat diseases related to protein disorders of any one or at least two or more of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7.

[0494] Preferably, the above-mentioned protein disorder is selected from protein overexpression.

[0495] Preferably, the above-mentioned protein disorder-related diseases are selected from: cancer, cardiovascular and cerebrovascular diseases, viral infection-related diseases, etc.

[0496] Preferably, the above-mentioned cancer is selected from the group consisting of leukemia, lymphoma, malignant glioma, medulloblastoma, melanoma, multiple myeloma, myelodysplastic syndrome, liver cancer, lung cancer, kidney cancer, pancreatic cancer, oral cancer, gastric cancer, esophageal cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, breast cancer, colon cancer, rectal cancer, bladder cancer, cervical cancer, ovarian cancer, prostate cancer, rhabdomyosarcoma, osteosarcoma, and chondrosarcoma; the viral infection-related diseases are selected from the group consisting of HIV, hepatitis B, hepatitis C, hepatitis A, influenza, epidemic encephalitis B, herpes, etc.; the leukemia includes chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute non-lymphocytic leukemia (ANLL), etc.

[0497] Preferably, the present invention provides the use of the compounds of the present invention and their pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs, and pharmaceutical compositions thereof in the preparation of a medicament for treating acute myeloid leukemia (AML). Further preferably, the pharmaceutical composition comprises a Bcl-2 selective inhibitor, wherein the Bcl-2 selective inhibitor is venetoclax (ABT-199), obatoclax mesylate (GX15-070), or APG-2575 (CAS No. 2180923-05-9). The compounds of the present invention and their pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, and prodrugs are used in combination or in conjunction with a Bcl-2 selective inhibitor; for example, the compounds of the present invention are used in combination or in conjunction with the Bcl-2 selective inhibitor venetoclax (ABT-199), which can solve the drug resistance problem associated with the use of the Bcl-2 selective inhibitor venetoclax (ABT-199) alone for the treatment of acute myeloid leukemia (AML). Another object of the present invention is to provide the use of the compounds of the present invention and pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof for preparing protein hydrolysis targeting chimeras (PROTACs), antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs) or small molecule-drug conjugates (SMDCs).

[0498] Beneficial effects of the present invention

[0499] The compounds provided by the present invention have excellent effects in degrading any one or more proteins including c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7, and can thus be used to prevent, alleviate or treat diseases associated with high expression of any one (such as c-Myc) or multiple proteins, such as cancer, cardiovascular and cerebrovascular diseases, viral infections and other diseases. The synthesis method of the compounds is simple, and the degradation effects of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7 proteins are precise and significant.

[0500] definition

[0501] Unless otherwise defined, the terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.The terms used in the specification are for describing particular embodiments only and are not intended to limit the invention.

[0502] In the present invention, Indicates the connection point of the connected parts.

[0503] The term "unsubstituted" shall mean substituted only with hydrogen atoms.

[0504] The term "substituted" or "optionally substituted" refers to the presence of one or more substituents, preferably 1-5 substituents, most preferably 1-3 substituents, at any carbon (or nitrogen) position in the molecule. The substituents may be hydroxyl, thiol, carboxyl, cyano, nitro, halogen (preferably 1, 2 or 3 halogens, especially on alkyl, especially methyl, such as trifluoromethyl), alkyl (preferably C1-C 10 , more preferably, C1-C6), haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl (especially phenyl), heteroaryl, heterocyclic, alkoxy (preferably C1-C6 alkoxy), aryloxy (preferably phenoxy), thioether (C1-C6 alkylthio or arylthio such as phenylthio), acyl (preferably C1-C6 acyl, arylformyl such as benzoyl), C1-C6 alkylamino, di(C1-C6 alkyl)amino, aminoacyl substituted by one or two C1-C6 alkyl groups (including aminoformyl optionally substituted by one or two C1-C6 alkyl groups), C1-C6 ester group, and the like.

[0505] The term "alkyl" refers to a linear, branched, fully saturated hydrocarbon or alkyl group that may be optionally substituted, preferably C1-C 10 , more preferably C1-C6, or C1-C4 alkyl. Examples of alkyl are methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

[0506] The term "alkylene" refers to a divalent group formed by removing a hydrogen atom from an alkyl group.

[0507] The term "cycloalkyl" refers to a cyclic hydrocarbon or alkyl group that may be optionally substituted, preferably a C3-C 20 , more preferably C3-C 15 , or C3-C8 alkyl. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexyl, cycloheptyl, and the like.

[0508] The term "cycloalkylene" refers to a divalent group formed by removing a hydrogen atom from a cycloalkyl group.

[0509] The term "bridged ring group" refers to a ring structure formed by two or more ring structures that may be optionally substituted and share two non-adjacent carbon atoms, preferably C5-C 15 , more preferably C6-C 12 , or C7-C10 Examples of bridged ring groups are bicyclo[1.1.1]pentanyl, norbornyl, adamantyl, and the like.

[0510] The term "alkenyl" refers to a linear, branched, or cyclic C2-C 10 (Preferably C2-C8) hydrocarbon group.

[0511] The term "alkynyl" refers to a linear, branched, or cyclic C2-C 10 (Preferably C2-C8) hydrocarbon group.

[0512] The term "aryl" refers to a C6-C16 aromatic group having a single ring (eg, phenyl) or condensed rings (eg, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, etc.) which may be optionally substituted, preferably a C6-C10 aromatic group.

[0513] The term "arylene group" refers to a divalent group formed by removing a hydrogen atom from an aryl group.

[0514] The term "heteroaryl" refers to an optionally substituted 5- to 16-membered aromatic group containing one or more heteroatoms selected from N, O, S or P, preferably a 5- to 10-membered aromatic group. Examples of heteroaryl groups include imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyrrolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, azaindolyl (e.g., 7-azaindolyl), benzimidazolyl, benzopyrazolyl, benzofuranyl, benzothienyl, benzothiazolyl, dibenzofuranyl, dibenzothienyl, quinolinyl, isoquinolinyl, naphthyridinyl, carbazolyl, azacarbazolyl (e.g., 1-azacarbazolyl, 2-azacarbazolyl, 1,8-diazacarbazolyl), indolizinyl, azaindolizinyl, phenoxazinyl, phenothiazinyl, and the like.

[0515] The term "heteroarylene" refers to a divalent group formed by further removing a hydrogen atom from a heteroaryl group.

[0516] The term "heterocyclyl" refers to a partially unsaturated or fully unsaturated 3-20 membered ring group, preferably a 3-10 membered ring group, more preferably a 3-6 membered ring group, which may be optionally substituted and contains one or more heteroatoms selected from N, O, S, SO, SO2 or P; the heterocyclyl group contains 1-19 carbon atoms, preferably 2-10 carbon atoms, more preferably 3-5 carbon atoms. Examples of heterocyclic groups include aziridine, oxirane, azetidinyl, oxetanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl, ethyleneurea, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, imidazolinyl, indolyl, morpholinyl, pyridone, 2-pyrrolidone, piperazinyl, homopiperazinyl, piperidinyl, homopiperidinyl, phthalimidyl, succinimidyl, pyrazinyl, pyrazolinyl, pyrrolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydrothiophenyl, oxanyl, oxathiolanyl, thianyl, and the like.

[0517] The term "heterocyclylene" refers to a divalent group formed by further removing a hydrogen atom from a heterocyclyl.

[0518] The term "heterocycloalkyl" refers to a fully saturated heterocyclic ring group.

[0519] The term "fused arylcycloalkyl" refers to a group in which the above-mentioned aryl group and cycloalkyl group are fused.

[0520] The term "fused arylheterocyclic group" refers to a group in which the above-mentioned aryl group and heterocyclic group are fused.

[0521] The term "fused heteroarylcycloalkyl" refers to a group in which the above-mentioned heteroaryl is fused with a cycloalkyl group.

[0522] The term "fused heteroarylheterocyclic group" refers to a group in which the above-mentioned heteroaryl group and heterocyclic group are fused.

[0523] The term "aryl-aryl" refers to the aforementioned aryl groups connected by a single bond, and the aryl group is connected to the other moiety. The terms "aryl-heteroaryl", "heteroaryl-aryl", "heteroaryl-heteroaryl" and so on are analogous.

[0524] The term "aryl-alkyl" refers to an aryl group and an alkyl group connected by a single bond, with the alkyl group connecting to the other moiety. The terms "heteroaryl-alkyl," "aryl-cycloalkyl," "aryl-heterocyclyl," "cycloalkyl-heterocyclyl," "heterocyclyl-heterocyclyl," and so on are analogous.

[0525] The term "halogen" refers to F, Cl, Br, I.

[0526] The term "pharmaceutically acceptable carrier" may refer to any and all solvents, dispersion media, coatings, antibacterial and antimicrobial agents, and the like, compatible with pharmaceutical administration.

[0527] Unless otherwise indicated, the term "compound" refers to any specific compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and, where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers), and pharmaceutically acceptable salts and derivatives thereof (including prodrug forms). When used in this context, the term compound generally refers not only to a single compound, but also to other compounds, such as stereoisomers, regioisomers and / or optical isomers (including racemic mixtures), as well as specific enantiomers or enantiomerically enriched mixtures of the disclosed compounds. The term also refers in this context to prodrug forms of compounds that have been modified to facilitate administration and delivery of the compound to the active site.

[0528] The term "protein proteolysis targeting chimeras (PROTAC)" is a hybrid bifunctional small molecule compound (Sakamoto KM. et al. Proc Natl Acad Sci USA, 2001, 98: 8554-8559), which includes a small molecule compound that can bind to a target protein (protein of interst, POI), a linker group at a suitable position thereof, and a small molecule compound that can bind to an E3 ubiquitin ligase.

[0529] The term "antibody-drug conjugate (ADC)" refers to a small molecule drug with biological activity connected to a monoclonal antibody through a chemical link. The monoclonal antibody acts as a carrier to transport the small molecule drug into target cells.

[0530] The term "peptide-drug conjugate (PDC)," also known as peptide-drug conjugate, is a novel molecular drug delivery system generally composed of a peptide, a covalent linker, and a payload. Typically, the drug (compound) is bound to the peptide via a covalent linker, imparting bidirectional functionality to the peptide and drug (compound), enhancing the drug's killing or targeting effects.

[0531] The term "small molecule-drug conjugate (SMDC)" refers to a novel molecular drug delivery system, typically consisting of a small molecule targeting ligand, a linker, and a payload. Typically, a drug (compound) is bound to the small molecule targeting ligand via a linker, imparting targeting functionality and promoting the drug's killing or targeting effects.

[0532] In addition, the entire text of international application number PCT / CN2022 / 100078 is also incorporated herein by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0533] FIG1 is a graph showing the degradation of c-Myc and GSPT1 proteins in HL60 cells by the compounds of the present invention. DETAILED DESCRIPTION

[0534] The present invention will be illustrated below with further detailed description. It should be noted that the following description is merely an illustration of the technical solutions claimed in the present invention and does not constitute any limitation on these technical solutions. The scope of protection of the present invention shall be determined by the contents of the appended claims.

[0535] Nuclear magnetic resonance (1H NMR) measurements were performed using a Bruker 400 MHz NMR instrument; the measurement solvents were deuterated methanol (CD3OD), deuterated chloroform (CDCl3), or hexadeuterated dimethyl sulfoxide (DMSO-d6); and the internal standard was tetramethylsilane (TMS).

[0536] The abbreviations used in the nuclear magnetic resonance (NMR) spectra in the examples are shown below. s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, qd: quartet doublet, ddd: double double doublet, ddt: double double triplet, dddd: double double double doublet, m: multiplet, br: broad, J: coupling constant, Hz: hertz, DMSO-d6: deuterated dimethyl sulfoxide. δ values ​​are expressed in ppm.

[0537] Abbreviations of test reagents:

[0538] Synthesis Example

[0539] Example 1

[0540] Synthesis of compound KT-001-1

[0541] Methyl 4-bromo-2-methylbenzoate (30.0 g, 131 mmol) was dissolved in 300 mL of carbon tetrachloride. NBS (28 g, 131 mmol) and AIBN (6.4 g, 40 mmol) were added. After reacting at 80°C for 1 hour, TLC indicated completion. The mixture was diluted with 150 mL of MTBE and filtered. The filtrate was washed with saturated sodium bicarbonate (30 mL x 3). The organic phase was dried and spin-dried to afford compound KT-001-1 (48 g, crude product).

[0542] Synthesis of compound KT-001-2

[0543] Compound KT-001-1 (48 g, 131 mmol) was dissolved in 450 mL of DMF, and 3-aminopiperidine-2,6-dione hydrochloride (28 g, 172 mmol) and potassium carbonate (65 g, 469 mmol) were added. After reacting at 70°C for 1 hour, TLC indicated completion. The reaction mixture was filtered, and the filtrate was vortexed to remove most of the solvent. The mixture was then slurried with 200 mL of dichloromethane / water (1:1) and filtered with suction. The filter cake was dried to yield compound KT-001-2 (19 g, 38% yield).

[0544] Synthesis of compound KT-001-3

[0545] Compound KT-001-2 (10 g, 31 mmol) was dissolved in 80 mL of DMF, and formic acid (5 g, 109 mmol), palladium acetate (209 mg, 0.93 mmol), DCC (1.3 g, 6.2 mmol), triethylamine (6.3 g, 62 mmol), and Xantphos (539 mg, 0.93 mmol) were added sequentially. Under nitrogen, the mixture was reacted at 100°C for 3 h, after which TLC indicated completion. The reaction mixture was filtered, and the filtrate was freed from most of the solvent by vortexing. The mixture was then slurried with 50 mL of dichloromethane and filtered with suction. The filter cake was dried to afford compound KT-001-3 (7.8 g, 88% yield). 1H NMR (400MHz, DMSO) δ11.02(s,1H),8.17(s,1H),8.00(d,J=7.9Hz,1H),7.96(s,1H),7.84(d,J=7.9Hz,1H),5.14(dd, J=13.3,5.1Hz,1H),4.55-4.37(m,2H),2.99-2.84(m,1H),2.69-2.58(m,1H),2.46-2.38(m,1H),2.07-1.95(m,1H).

[0546] Synthesis of compound KT-001-4

[0547] Compound KT-001-3 (730 mg, 2.53 mmol), 1-(N-Boc-aminomethyl)-4-(aminomethyl)benzene (600 mg, 2.53 mmol), and DIPEA (1.96 g, 15.18 mmol) were added sequentially to 20 mL of DMF. HATU (1.15 g, 3.04 mmol) was added under ice-cooling. After reacting at room temperature for 1 h, TLC indicated that the reaction was complete. 120 mL of water / ethyl acetate (1:1) was added, the mixture was stirred for 1 h, and then filtered. The filter cake was washed with ethyl acetate and dried to obtain compound KT-001-4 (710 mg, 55% yield). NMR (400MHz, DMSO) δ11.01(s,1H),9.21(t,J=5.8Hz,1H),8.09(s,1H),8.01(d,J=8. 3Hz,1H),7.82(d,J=8.0Hz,1H),7.36(s,1H),7.28(d,J=7.8Hz,2H),7.19(d,J=7.9H z,2H),5.14(dd,J=13.3,5.0Hz,1H),4.56–4.36(m,4H),4.09(d,J=5.9Hz,2H),2.97 –2.85(m,1H),2.69–2.57(m,1H),2.46–2.37(m,1H),2.08–1.98(m,1H),1.38(s,9H).

[0548] Synthesis of compound KT-001-5

[0549] Compound KT-001-4 (710 mg, 1.4 mmol) was dissolved in dichloromethane (20 mL), and HCl-Dioxane (10 mL, 4 M) was added. After reacting at room temperature for 1 hour, TLC monitoring indicated complete reaction. The solvent was evaporated to afford compound KT-001-5 (700 mg, crude), which was used directly in the next reaction.

[0550] Synthesis of compound KT-001-6

[0551] Compound KT-001-5 (700 mg, 1.4 mmol) and phenylacetaldehyde (185 mg, 1.5 mmol) were dissolved in methanol (10 mL). After stirring at room temperature for 5 minutes, NaBH3CN (132 mg, 2.1 mmol) was added. After continuing the reaction at room temperature for 2 hours, TLC indicated completion of the reaction. Aq. NaHCO3 (30 mL) was added to the reaction solution, which was then extracted with dichloromethane (35 mL x 3). The organic phases were combined, dried, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 15:1) to obtain compound KT-001-6 (600 mg, 84% yield). ESI-MS (M+H)+: 511.2.

[0552] Synthesis of compound KT-001

[0553] Compound KT-001-6 (600 mg, 1.17 mmol), 2-bromoethanol (293 mg, 3.51 mmol), and DIPEA (452 ​​mg, 3.5 mmol) were dissolved in DMF (15 mL). After stirring at 80°C overnight, TLC indicated completion of the reaction. The reaction was quenched by adding water (50 mL). The aqueous phase was extracted with ethyl acetate (50 mL x 3). The combined organic phases were then washed with saturated brine (30 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 15:1) to obtain compound KT-001 (200 mg, 31% yield). 1H NMR (400MHz, DMSO) δ11.01(s,1H),9.22(s,1H),8.10(s,1H),8.01(d,J=8.0Hz,1H),7.82(d,J=7.9Hz,1H),7.39–7.10(m,9H),5.13(dd,J=13.2,5. 1Hz,1H),4.60–4.32(m,4H),3.78-3.48(m,6H),2.98–2.86(m,1H),2.83– 2.53(m,5H),2.46–2.31(m,1H),2.09–1.96(m,1H).ESI-MS(M+H)+:555.3.

[0554] The synthesis methods of KT-002 and KT-003 refer to KT-001

[0555] 1H NMR (400MHz, DMSO) δ11.01(s,1H),9.20(t,J=6.1Hz,1H),8.10(s,1H),8.01(d,J=7.7Hz, 1H),7.82(d,J=7.9Hz,1H),7.49-7.46(m,2H),7.25-7.14(m,5H),5.14(dd,J=13.3,5.1H z,1H),4.55-4.28(m,5H),3.62(s,2H),3.46-3.39(m,2H),2.98-2.85(m,1H),2.77-2.65 (m,4H),2.63–2.51(m,3H),2.42(dd,J=12.9,4.5Hz,1H),2.06-1.98(m,1H).ESI-MS(M+H) + :623.2.

[0556] 1 H NMR (400MHz, DMSO) δ11.01(s,1H),9.22(t,J=6.0Hz,1H),8.11(s,1H),8.03(d,J=8.1Hz,1H),7. 89–7.80(m,3H),7.73(d,J=7.9Hz,1H),7.45-7.36(m,3H),7.35–7.24(m,5H),5.14(dd,J=13.3,5 .1Hz,1H),4.58–4.34(m,5H),3.74(s,2H),3.50(t,J=6.4Hz,2H),3.23–3.14(m,2H),2.98–2.83( m,1H),2.81–2.72(m,2H),2.71–2.56(m,3H),2.46–2.32(m,1H),2.06–2.00(m,1H).ESI-MS(M+H) + :605.3.

[0557] Example 2

[0558] Synthesis of compound KT-004-1

[0559] 2-(1-Naphthyl)ethanol (860 mg, 5 mmol) was dissolved in 18 mL of DCM, and Dess-Martin reagent (3.18 g, 7.5 mmol) was added portionwise at 0°C. After 2 h of reaction at room temperature, TLC indicated the reaction was complete and the mixture was filtered. Aq. NaHCO₃ (30 mL) was added to the filtrate, followed by extraction with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 100:1–15:1) to afford compound KT-004-1 (690 mg, 81% yield).

[0560] Synthesis of compound KT-004-2

[0561] Compound KT-004-1 (690 mg, 4.1 mmol) and 1-(N-Boc-aminomethyl)-4-(aminomethyl)benzene (968 mg, 4.1 mmol) were dissolved in 12 mL of methanol, and NaBH3CN (504 mg, 8 mmol) and AcOH (100 mg) were added. After reacting at room temperature for 4 h, TLC indicated the reaction was complete. After adding aq. NaHCO3 (30 mL), the mixture was extracted with dichloromethane (35 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 20:1) to obtain compound KT-004-2 (540 mg, 34% yield). ESI-MS (M+H) + :391.2.

[0562] Synthesis of compound KT-004-3

[0563] Compound KT-004-2 (540 mg, 1.38 mmol) and glycolic acid (106 mg, 1.4 mmol) were dissolved in 10 mL of dichloromethane, and HATU (630 mg, 1.66 mmol) and TEA (420 mg, 4.2 mmol) were added. After reacting at room temperature for 2 h, TLC showed that the reaction was complete. Water (30 mL) was added to quench the reaction, and the aqueous phase was extracted with dichloromethane (35 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was dried by spin drying. The crude product was purified by column chromatography (eluent: dichloromethane: methanol = 20:1) to obtain compound KT-004-3 (406 mg, yield 65%). ESI-MS (M+H) + :449.2.

[0564] Synthesis of compound KT-004-4

[0565] Compound KT-004-3 (406 mg, 0.9 mmol) was dissolved in 4 mL of tetrahydrofuran and HCl-Dioxane (3 mL, 4 M) was added. After 4 h at room temperature, TLC indicated the reaction was complete. The solvent was evaporated to afford compound KT-004-4 (400 mg, crude product), which was used directly in the next reaction.

[0566] Synthesis of compound KT-004

[0567] Compound KT-004-4 (400 mg, 0.89 mmol) and compound KT-001-3 (259 mg, 0.9 mmol) were dissolved in 10 mL of dichloromethane, and HATU (410 mg, 1.1 mmol) and triethylamine (270 mg, 2.7 mmol) were added. After 1.5 h of reaction at room temperature, TLC indicated the reaction was complete. The reaction was quenched with water (50 mL), and the aqueous phase was extracted with dichloromethane (35 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 15:1) to obtain compound KT-004 (127 mg, 23% yield) as a white solid. 1 H NMR (400MHz, DMSO) δ11.00(s,1H),9.21(d,J=4.2Hz,1H),8.14(d,J=7.9Hz,1H),8.07(s,1H),8.02-7.98( m,1H),7.92-7.88(m,1H),7.83–7.73(m,2H),7.57–7.45(m,2H),7.43–7.27(m,4H),7.24-7.19(m,2H),5.1 3(dd,J=13.2,5.0Hz,1H),4.62(s,1H),4.53–4.32(m,5H),4.16(s,1H),3.96(s,1H),3.53-3.44(m,1H),3. 30-3.13(m,3H),3.00–2.84(m,1H),2.66-2.55(m,1H),2.47–2.27(m,1H),2.05–1.93(m,1H).ESI-MS(M+H) + :619.3.

[0568] The synthesis operation of KT-016 and KT-033 refers to KT-004

[0569] 1H NMR (400MHz, DMSO) δ11.01(s,1H),9.23(t,J=6.0Hz,1H),8.10(s,1H),8.02(d,J=8.0Hz,1H),7. 82(d,J=7.9Hz,1H),7.42–7.25(m,5H),7.22-7.15(m,4H),5.14(dd,J=13.3,5.1Hz,1H),4.75(br s,1H),4.59–4.32(m,8H),4.17(d,J=3.6Hz,2H),2.99–2.84(m,1H),2.66–2.54(m,1H),2.47–2.32(m,1H),2.07-1.97(m,1H).ESI-MS(M+H) + :555.3.

[0570] 1 H NMR (400MHz, DMSO) δ11.00(s,1H),9.20(dd,J=13.9,6.0Hz,1H),8.09(s,1H),8.00(d,J=7.9Hz, 1H),7.81(d,J=7.9Hz,1H),7.34-7.24(m,4H),7.23-7.15(m,5H),5.14(dd,J=13.3,5.1Hz,1H), 4.56–4.35(m,7H),3.69–3.57(m,2H),3.42(t,J=7.5Hz,2H),2.98–2.85(m,1H),2.81(t,J=7.6H z,1H),2.78–2.69(m,1H),2.66-2.54(m,1H),2.48-2.34(m,3H),2.07–1.96(m,1H).ESI-MS(M+H) + :583.4.

[0571] Example 3

[0572] Synthesis of compound KT-005-1

[0573] 1-Bromocarbazole (1.2 g, 4.9 mmol) was added to 50 mL of THF. NaH (590 mg, 14.6 mmol, 60%) was added under an ice bath. The reaction was allowed to proceed at room temperature for 1 h, followed by the addition of tert-butyl bromoacetate (1.14 g, 5.9 mmol). After overnight reaction at room temperature, TLC indicated completion. The reaction was quenched by the addition of water (60 mL). The aqueous phase was extracted with ethyl acetate (80 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated. The solute was separated by column chromatography (mobile phase: petroleum ether:ethyl acetate = 10:1) to afford compound KT-005-1 (700 mg, 40% yield).

[0574] Synthesis of compound KT-005-2

[0575] Dissolve compound KT-005-1 (700 mg, 1.9 mmol) in 15 mL of dichloromethane and add 5 mL of trifluoroacetic acid. Allow to react at room temperature for 1 hour. TLC indicates completion. The solution is then spin-dried to afford compound KT-005-2 (700 mg, crude product), which is used directly in the next reaction.

[0576] Synthesis of compound KT-005-3

[0577] Compound KT-005-2 (700 mg, 1.9 mmol) was dissolved in 40 mL of DCM, and 1-(N-Boc-aminomethyl)-4-(aminomethyl)benzene (560 mg, 2.4 mmol), HATU (1.1 g, 2.9 mmol), and triethylamine (800 mg, 7.9 mmol) were added. After reacting at room temperature overnight, TLC indicated completion. The reaction was quenched with water (20 mL) and extracted with dichloromethane (80 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated. The solute was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 1:1) to afford compound KT-005-3 (800 mg, 78% yield). 1 H NMR (400MHz, DMSO) δ8.66(t,J=6.0Hz,1H),8.22–8.19(m,2H),7.59(dd,J=11.2,7.7Hz,2H),7.52–7.45(m,1H),7.36( s,1H),7.29–7.25(m,1H),7.22–7.11(m,5H),5.47(s,2H),4.28(d,J=5.8Hz,2H),4.09(d,J=5.8Hz,2H),1.39(s,9H).

[0578] Synthesis of compound KT-005-4

[0579] Compound KT-005-3 (500 mg, 0.9 mmol), zinc cyanide (230 mg, 1.9 mmol), Pd2(dba)3 (170 mg, 0.2 mmol), and DPPF (200 mg, 0.4 mmol) were dissolved in 18 mL of DMF. Under nitrogen, the mixture was reacted at 120°C overnight, and TLC indicated completion. The reaction was quenched with water (60 mL) and extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated. The product was purified by column chromatography (mobile phase: dichloromethane:methanol = 20:1) to afford compound KT-005-4 (370 mg, 82% yield). 1 H NMR (400MHz, DMSO) δ8.82(t,J=5.7Hz,1H),8.55(d,J=7.7Hz,1H),8.29(d,J=7.7Hz,1H),7.87(d,J=7.4Hz,1H),7.64(d,J=8.3Hz,1H),7.57–7.53 (m,1H),7.41–7.32(m,3H),7.24(d,J=8.1Hz,2H),7.17(d,J=8.1Hz,2H) ,5.43(s,2H),4.31(d,J=5.6Hz,2H),4.09(d,J=6.1Hz,2H),1.36(s,9H).

[0580] Synthesis of compound KT-005-5

[0581] Compound KT-005-4 (300 mg, 0.6 mmol) was dissolved in 10 mL of pyridine, 3 mL of AcOH, and 3 mL of water. Sodium hypophosphite (650 mg, 6.0 mmol) and Raney nickel (1 g) were added thereto. After reacting at room temperature overnight, TLC showed that the reaction was complete. The reaction solution was filtered, and the filtrate was added with saturated sodium bicarbonate (40 mL) and extracted with ethyl acetate (80 mL*3). The organic phases were combined and washed with saturated brine (20 mL*2), then dried over anhydrous sodium sulfate and the solvent was dried by spin drying to obtain compound KT-005-5 (350 mg, crude product), which was directly used in the next reaction. ESI-MS (M+H) + :472.3.

[0582] Synthesis of compound KT-005-6

[0583] Compound KT-005-5 (350 mg, 0.6 mmol) was dissolved in 25 mL of methanol and sodium borohydride (40 mg, 1.1 mmol) was added under ice-cooling. After 2 h of reaction at room temperature, TLC indicated that the reaction was complete. Water (20 mL) was added to quench the reaction and the mixture was extracted with dichloromethane (60 mL*3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was dried by spin-drying. The solute was purified by column chromatography (mobile phase: dichloromethane: methanol = 20:1) to obtain compound KT-005-6 (80 mg, yield 26%). ESI-MS (M-H2O+H) + :456.3.

[0584] Synthesis of compound KT-005-7

[0585] Compound KT-005-6 (80 mg, 0.17 mmol) was dissolved in 5 mL of dichloromethane and HCl / dioxane (3 mL, 4 M) was added. After 1 h of reaction at room temperature, TLC indicated that the reaction was complete. The solvent was then dried to obtain compound KT-005-7 (80 mg, crude product), which was used directly in the next reaction. Synthesis of Compound KT-005

[0586] Compound KT-005-7 was dissolved in 15 mL of DCM, and compound KT-001-3 (50 mg, 0.17 mmol), HATU (90 mg, 0.24 mmol), and triethylamine (65 mg, 0.6 mmol) were added. After reacting overnight at room temperature, TLC indicated completion. The reaction was quenched by adding water (20 mL), and the aqueous phase was extracted with dichloromethane (80 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated. The solute was purified by column chromatography (mobile phase: dichloromethane:methanol = 10:1) to obtain compound KT-005 (24 mg, 23% yield). 1H NMR (400MHz, DMSO) δ11.01(s,1H),9.22(t,J=5.9Hz,1H),8.71(t,J=5.9Hz,1H),8.18–8.10(m,2H),8.08(s,1H),8.00(d,J=8.0 Hz,1H),7.82(d,J=7.9Hz,1H),7.48(d,J=8.2Hz,1H),7.45-7.40(m,1H),7.33(d,J=6.6Hz,1H),7.28(d,J=8.1Hz,2H),7.24–7. 18(m,3H),7.17-7.12(m,1H),5.55(t,J=5.3Hz,1H),5.41(s,2H),5.13(dd,J=13.3,5.1Hz,1H),4.77(d,J=5.3Hz,2H),4.55-4. 37(m,4H),4.28(d,J=5.8Hz,2H),2.99–2.85(m,1H),2.68-2.56(m,1H),2.46–2.32(m,1H),2.12–1.99(m,1H).ESI-MS(M-H2O+H) + :626.3.

[0587] Example 4

[0588] Synthesis of compound KT-006-1

[0589] 3-Hydroxy-4-methylbenzonitrile (2.66 g, 20 mmol) was dissolved in DMF (30 ml), and bromoethanol (3.75 g, 30 mmol) and potassium carbonate (8.28 g, 60 mmol) were added. After reacting at 80°C for 3 hours, TLC showed that the reaction was complete. The reaction solution was cooled to room temperature, water (300 ml) was added, and then extracted with ethyl acetate (100 mL*2). The organic phases were combined and washed with saturated brine (50 mL*2). The organic phases were collected, dried, filtered, and the solvent was evaporated to obtain KT-006-1 (2.55 g, 72% yield). 1 H NMR (400MHz, DMSO) 7.37 (s, 1H), 7.34-7.29 (m, 2H), 4.88 (t, J = 4.0Hz, 1H), 4.07 (t, J = 4.0Hz, 2H), 2.23 (s, 3H).

[0590] Synthesis of compound KT-006-2

[0591] Compound KT-006-1 (2.55 g, 14.4 mmol) was dissolved in DCM (30 ml) and TEA (2.91 g, 28.8 mmol) was added. Acetyl chloride (1.36 g, 17.3 mmol) was slowly added under an ice bath. Upon completion of the addition, the temperature was raised to 20°C. After 3 hours of reaction, TLC indicated completion. The mixture was poured into ice water (100 ml) and extracted with ethyl acetate (100 mL x 2). The organic phases were combined and washed with saturated brine (50 mL x 2). The organic phases were collected, dried, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 5:1) to afford KT-006-2 (2.65 g, 85% yield).

[0592] Synthesis of compound KT-006-3

[0593] Compound KT-006-2 (2.65 g, 12.1 mmol) was dissolved in carbon tetrachloride (40 ml), and NBS (2.15 g, 12.1 mmol) and AIBN (0.40 g, 2.42 mmol) were added. After reacting at 80°C for 3 hours, TLC indicated the reaction was complete. The reaction solution was spin-dried, and the crude product was purified by column chromatography (petroleum ether:ethyl acetate = 4:1) to obtain KT-006-3 (2.25 g, 63% yield).

[0594] Synthesis of compound KT-006-4

[0595] Compound KT-006-3 (1.49 g, 5.0 mmol) and NaN3 (0.325 g, 5.0 mmol) were dissolved in DMF (15 ml). After 3 hours of reaction at room temperature, TLC indicated completion of the reaction. Water (50 ml) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (100 mL x 2), and the combined organic phases were washed with saturated brine (50 mL x 2). The organic phases were collected, dried, filtered, and the solvent was evaporated to obtain compound KT-006-4 (1.3 g, 100% yield).

[0596] Synthesis of compound KT-006-5

[0597] Compound KT-006-4 (1.3 g, 5.0 mmol) and triphenylphosphine (1.31 g, 5.0 mmol) were dissolved in THF / H2O (20 ml / 5 ml). After 5 hours of reaction at room temperature, TLC showed that the reaction was complete. Dilute hydrochloric acid (1 M, 50 ml) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (50 ml*2), and the pH of the aqueous phase was adjusted to 10 with saturated sodium carbonate solution. The aqueous phase was extracted with ethyl acetate (50 ml*3). The organic phases were combined, dried, filtered, and the solvent was dried to obtain compound KT-006-5 (1.3 g, yield 100%). ESI-MS (M+H)+ :235.2.

[0598] Synthesis of compound KT-006-6

[0599] Compound KT-006-5 (1.17 g, 5.0 mmol) was dissolved in ethyl acetate (50 ml), and saturated sodium bicarbonate solution (20 ml) was added thereto. FmocCl (2.1 g, 7.5 mmol) was then added thereto under ice bath. After reacting at room temperature for 3 hours, TLC showed that the reaction was complete. Water (50 ml) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (100 ml*2), and the organic phases were combined. Dry, filter, and spin-dry the solvent. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound KT-006-6 (1.3 g, 57%). ESI-MS (M+H) + :457.2.

[0600] Synthesis of compound KT-006-7

[0601] Compound KT-006-6 (1.3 g, 2.85 mmol) was dissolved in 40 ml of methanol, and (Boc)2O (1.24 g, 5.7 mmol) and Raney nickel (2.0 g) were added. After reacting at room temperature for 2 hours under a hydrogen atmosphere, TLC indicated the reaction was complete. The reaction solution was filtered, and the filtrate was dried to obtain compound KT-006-7 (1.15 g, 72% yield). ESI-MS (M+H) + :561.2.

[0602] Synthesis of compound KT-006-8

[0603] Compound KT-006-7 (1.15 g, 2.1 mmol) was dissolved in 20 ml of dichloromethane and trifluoroacetic acid (4 ml) was added. After 2 hours at room temperature, TLC indicated the reaction was complete. The solvent was evaporated to give compound KT-006-8 (1.3 g, crude product), which was used directly in the next reaction.

[0604] Synthesis of compound KT-006-10

[0605] Compound KT-006-8 (0.97 g, 2.1 mmol), compound KT-006-9 (475 mg, 2.1 mmol), and DIPEA (0.81 g, 6.3 mmol) were dissolved in DMF (20 ml). HATU (0.96 g, 2.52 mmol) was slowly added under ice-cooling. After the addition and reaction at room temperature for 2 hours, TLC indicated that the reaction was complete. Ice water (100 ml) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (200 mL*2). The organic phases were combined and washed again with saturated brine (50 mL*2). The organic phases were collected, dried, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:1) to obtain compound KT-006-10 (1.05 g, yield 75%). ESI-MS (M+H) + :669.3.

[0606] Synthesis of compound KT-006-11

[0607] Compound KT-006-10 (335 mg, 0.5 mmol) was dissolved in 30 mL of methanol. Aqueous lithium hydroxide solution (5 mL, 2 M) was slowly added under an ice bath. After 16 hours of reaction at room temperature, TLC indicated completion. The mixture was diluted with water (100 mL). The aqueous phase was extracted with ethyl acetate (100 mL x 3), and the combined organic phases were washed again with saturated brine (50 mL x 2). The organic phases were collected, dried, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:1) to afford compound KT-006-11 (202 mg, 100% yield).

[0608] Synthesis of compound KT-006

[0609] Intermediate KT-006-11 (202 mg, 0.5 mmol), KT-001-3 (144 mg, 0.5 mmol), and DIPEA (194 mg, 1.5 mmol) were dissolved in 10 mL of DMF. HATU (228 mg, 0.6 mmol) was slowly added under ice-cooling. After 2 hours of reaction at room temperature, TLC indicated completion. The reaction was quenched by adding ice water (100 mL). The aqueous phase was extracted with ethyl acetate (200 mL x 2). The combined organic phases were washed with saturated brine (50 mL x 2). The organic phases were collected, dried, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (dichloromethane:methanol = 15:1) to afford compound KT-006 (22 mg, 7% yield). 1H NMR (400MHz, DMSO) δ11.01(s,1H),8.94(t,J=5.8Hz,1H),8.72(t,J=5.9Hz,1H),8.55(dd,J=7.6,1.4Hz,1H),8.44(dd,J=4.8,1.4Hz,1H),8.21(d ,J=7.7Hz,1H),8.09(s,1H),8.00(d,J=8.1Hz,1H),7.82(d,J=7.9Hz,1H ),7.58(d,J=8.2Hz,1H),7.49(t,J=7.7Hz,1H),7.32–7.23(m,2H),7.16( d,J=7.7Hz,1H),6.87(s,1H),6.82(d,J=7.8Hz,1H),5.20–5.10(m,3H), 4.94(t,J=5.7Hz,1H),4.47(dt,J=41.6,17.7Hz,4H),4.28(d,J=5.8Hz,2 H),3.99(t,J=4.9Hz,2H),3.76(dd,J=10.2,5.2Hz,2H),2.99–2.85(m,1H ),2.65–2.56(m,1H),2.47–2.36(m,1H),2.06–1.95(m,1H).ESI-MS(M+H) + :675.3.

[0610] Example 5

[0611] Synthesis of compound KT-017-1

[0612] 4-Bromo-2-chlorophenol (600 mg, 2.9 mmol) and N-Boc-piperazine (680 mg, 3.6 mmol) were dissolved in 30 mL of toluene. LiHMDS (6.6 mL, 1 M), Pd(dba) (120 mg, 0.15 mmol), and 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphoric acid bicyclo[3.3.3]undecane (120 mg, 0.3 mmol) were added. The mixture was reacted at 80°C under nitrogen overnight. TLC indicated the reaction was complete. Water (60 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether: ethyl acetate = 4:1) to obtain compound KT-017-1 (270 mg, yield 30%). ESI-MS (M+H) + :313.2.

[0613] Synthesis of compound KT-017-2

[0614] KT-017-1 (270 mg, 0.86 mmol) was dissolved in 5 mL of dichloromethane and HCl / dioxane (5 mL, 4 M) was added. After 1 h of reaction at room temperature, TLC indicated the reaction was complete. The solvent was evaporated to give compound KT-017-2 (280 mg, crude product), which was used directly in the next reaction.

[0615] Synthesis of compound KT-017-3

[0616] Compound KT-017-2 (280 mg, crude product) and methyl paraformylbenzoate (170 mg, 1.0 mmol) were dissolved in 18 mL of methanol, and a catalytic amount of acetic acid was added. After reacting at room temperature for 2 h, sodium cyanoborohydride (110 mg, 1.7 mmol) was added. After reacting at room temperature overnight, TLC indicated that the reaction was complete. Water (60 mL) was added to quench the reaction, and the aqueous phase was extracted with dichloromethane (60 mL*3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated. The solute was purified by column chromatography (mobile phase: petroleum ether: ethyl acetate = 1:1) to obtain compound KT-017-3 (160 mg, 50% yield). ESI-MS (M+H) + :361.2.

[0617] Synthesis of compound KT-017-4

[0618] Compound KT-017-3 (80 mg, 0.2 mmol) was dissolved in methanol / water (12 mL / 4 mL) and lithium hydroxide (30 mg, 0.6 mmol) was added. After reacting at 60°C for 1 hour, TLC indicated the reaction was complete. The mixture was cooled to room temperature and the pH was adjusted to 4 with 2N dilute hydrochloric acid. The resulting product, compound KT-017-4 (150 mg, crude), was dried and used directly in the next step.

[0619] Synthesis of compound KT-017

[0620] Compounds KT-017-4 (150 mg, crude) and KT-017-5 (86 mg, 0.28 mmol) were dissolved in 20 mL of dichloromethane. HATU (130 mg, 0.35 mmol) and triethylamine (95 mg, 0.9 mmol) were added. After reacting at room temperature overnight, TLC indicated completion. The reaction was quenched with water (20 mL), and the aqueous phase was extracted with DCM (80 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: dichloromethane:methanol = 20:1) to obtain compound KT-017 (7 mg, 5% yield). 1H NMR(400MHz,DMSO)δ10.96(s,1H),9.40(br s,1H),9.10(t,J=5.9Hz,1H),7.88(d,J=8.2Hz,2H),7.69(d,J=7.8Hz,1H),7.54(s,1H),7.47- 7.41(m,3H),6.88-6.80(m,2H),6.75(dd,J=8.9,2.8Hz,1H),5.09(dd,J=13.3,5.1Hz,1H),4.59 (d,J=5.7Hz,2H),4.37(dd,J=53.7,17.3Hz,2H),3.57(s,2H),3.04-2.96(m,4H),2.94–2.85(m ,1H),2.64-2.56(m,1H),2.49–2.47(m,4H),2.43–2.31(m,1H),2.04–1.97(m,1H).ESI-MS(M+H) + :602.3.

[0621] Reference KT-017 to synthesize KT-018

[0622] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),9.11(t,J=5.9Hz,1H),7.88(d,J=8.2Hz,2H),7.69(d,J=7.8 Hz,1H),7.54(s,1H),7.47-7.42(m,3H),7.32(d,J=9.2Hz,1H),6.92-6.86(m,2H),5.14-5.06( m,2H),4.59(d,J=5.9Hz,2H),4.48-4.24(m,4H),3.58(s,2H),3.18-3.08(m,4H),2.97–2.83(m ,1H),2.64-2.55(m,1H),2.49–2.48(m,4H),2.43-2.30(m,1H),2.08–1.88(m,1H).ESI-MS(M+H) + :616.3.

[0623] The intermediate KT-018-2 corresponding to KT-018 was synthesized as follows:

[0624] Synthesis of compound KT-018-1

[0625] Methyl 2-chloro-4-fluorobenzoate (3.0 g, 16.0 mmol) and N-Boc piperazine (3.56 g, 19.1 mmol) were dissolved in 20 mL of DMSO. After reacting at 80°C for 2 h, TLC indicated the reaction was complete. Water (60 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 5:1) to afford compound KT-018-1 (4.1 g, 72% yield).

[0626] Synthesis of compound KT-018-2

[0627] Compound KT-018-1 (2.20 g, 6.21 mmol) was dissolved in 10 mL of dichloromethane. Diisobutylaluminum hydride (12 mL, 1 M, 12 mmol) was added dropwise at -20°C. After 2 h of reaction at -20°C, TLC indicated completion. The reaction was quenched with saturated ammonium chloride solution (60 mL). The aqueous phase was extracted with dichloromethane (50 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 3:1) to afford compound KT-018-2 (1.4 g, 69% yield).

[0628] Example 6

[0629] Synthesis of compound KT-019-1

[0630] Compound KT-017-3 (80 mg, 0.2 mmol) and benzyl 2-bromoethyl ether (75 mg, 0.3 mmol) were dissolved in 12 mL of DMF, and cesium carbonate (145 mg, 0.4 mmol) was added. After reacting at 90°C for 2 h, TLC indicated that the reaction was complete. Water (60 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (60 mL*3). The combined organic phases were washed with saturated brine (10 mL*3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether: ethyl acetate = 4:1) to obtain compound KT-019-1 (85 mg, yield 77%). ESI-MS (M+H) + :495.2.

[0631] The synthesis operations of KT-019-2 and KT-019-3 refer to KT-017-4 and KT-017

[0632] Synthesis of compound KT-019

[0633] Compound KT-019-3 (25 mg, 0.034 mmol) was dissolved in 10 mL of DCM and a 1 M solution of BCl₃ (1 mL) was added under ice. The reaction was allowed to proceed at room temperature for 1 h, and TLC indicated completion. The reaction was quenched with methanol (5 mL), and the solvent was evaporated. The crude product was purified by column chromatography (mobile phase: dichloromethane:methanol = 20:1) to afford compound KT-019 (15 mg, 68% yield). 1 H NMR (400MHz, DMSO) δ9.11(t,J=6.0Hz,1H),7.88(d,J=8.1Hz,2H),7.69(d,J=7.8Hz,1H),7.54(s,1H),7.48-7.42(m, 3H),7.02(d,J=9.0Hz,1H),6.97(d,J=2.8Hz,1H),6.84(dd,J=9.0,2.8Hz,1H),5.09(dd,J=13.3,5.1Hz,1H),4.59(d ,J=5.8Hz,2H),4.37(dd,J=53.8,17.3Hz,2H),3.96(t,J=5.1Hz,2H),3.69(t,J=5.1Hz,2H),3.57(s,2H),3.10-3.00 (m,4H),2.95–2.85(m,1H),2.64–2.54(m,1H),2.49–2.48(m,4H),2.43–2.30(m,1H),2.04-1.97(m,1H).ESI-MS(M+H) + :646.3.

[0634] Example 7

[0635] Synthesis of compound KT-020-1

[0636] Methyl 4-methylsalicylate (500 mg, 3.0 mmol) was dissolved in 15 mL of carbon tetrachloride, and NBS (587 mg, 3.3 mmol) and AIBN (148 mg, 0.9 mmol) were added. After stirring at 80°C overnight, TLC indicated the reaction was complete. Water (40 mL) was added to quench the reaction, and the aqueous phase was extracted with dichloromethane (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, and spin-dried to obtain compound KT-020-1 (800 mg, crude product), which was used directly in the next reaction.

[0637] Synthesis of compound KT-020-2

[0638] Compound KT-020-1 (800 mg, crude product) and N-Boc piperazine (558 mg, 3.0 mmol) were dissolved in 8 mL of tetrahydrofuran, and triethylamine (303 mg, 3.0 mmol) was added. After reacting at room temperature for 2 h, TLC showed that the reaction was complete. Water (40 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (30 mL*3). The organic phases were combined and washed with saturated brine (10 mL*3), then dried over anhydrous sodium sulfate and spin-dried. The crude product was purified by column chromatography (mobile phase: petroleum ether: ethyl acetate = 6:1) to obtain compound KT-020-2 (544 mg, yield 52%). ESI-MS (M+H) + :351.2.

[0639] Synthesis of compound KT-020-3

[0640] KT-020-2 (144 mg, 0.41 mmol) was dissolved in 5 mL of dichloromethane and HCl / dioxane (5 mL, 4 M) was added. After 1 h of reaction at room temperature, TLC indicated that the reaction was complete. The solvent was dried to obtain compound KT-020-3 (150 mg, crude product), which was used directly in the next reaction. Synthesis of compound KT-020-4

[0641] KT-020-3 (150 mg, crude) and 2-chloro-4-iodo-methylbenzene (103 mg, 0.41 mmol) were dissolved in 6 mL of dioxane, and potassium tert-butoxide (92 mg, 0.82 mmol), Pd2(dba)3 (56 mg, 0.062 mmol), and Xphos (39 mg, 0.082 mmol) were added. The mixture was reacted at 100°C overnight under nitrogen protection, and TLC indicated completion. Water (40 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine (20 mL). The organic phases were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 2:1) to obtain compound KT-020-4 (50 mg, 80% yield). ESI-MS (M+H) + :375.2.

[0642] The synthesis operation of KT-020-5 and KT-020 refers to KT-017-4 and KT-017

[0643] 1H NMR (400MHz, DMSO) δ10.97(s,1H),9.39(t,J=5.9Hz,1H),7.88(d,J=8.1Hz,1H),7.71(d,J=7.7Hz,1H),7.56(s, 1H),7.48(d,J=7.4Hz,1H),7.15(d,J=8.5Hz,1H),6.94-6.86(m,3H),6.82(dd,J=8.4,2.5Hz,1H),5.10(dd,J=13 .3,5.1Hz,1H),4.63(d,J=6.1Hz,2H),4.39(dd,J=54.6,17.5Hz,2H),3.51(s,2H),3.16-3.09(m,4H),2.97–2.8 5(m,1H),2.68–2.56(m,1H),2.49–2.48(m,4H),2.42–2.31(m,1H),2.21(s,3H),2.07-1.97(m,1H).ESI-MS(M+H) + :616.3.

[0644] KT-021 was synthesized by referring to the synthesis method of KT-020

[0645] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),8.94(t,J=6.0Hz,1H),7.79(d,J=7.9Hz,1H),7.69(d,J=7.8Hz,1H),7.57(s,1H),7.49(d, J=7.9Hz,1H),7.19–7.11(m,2H),7.03(d,J=8.0Hz,1H),6.92(d,J=2.4Hz,1H),6.82(dd,J=8.5,2.5Hz,1H),5.14-5.04(m,2H) ,4.62(d,J=6.0Hz,2H),4.37(dd,J=53.2,17.4Hz,2H),4.19(t,J=4.7Hz,2H),3.81-3.74(m,2H),3.56(s,2H),3.17-3.06(m,4 H),2.96–2.84(m,1H),2.65-2.55(m,1H),2.52-2.51(m,4H),2.44-2.31(m,1H),2.20(s,3H),2.04–1.93(m,1H).ESI-MS(M+H) + :660.3.

[0646] Among them, the intermediate KT-021-1 corresponding to KT-021 was synthesized as follows:

[0647] Compound KT-020-4 (96 mg, 0.26 mmol) and 2-bromoethanol (38 mg, 0.3 mmol) were dissolved in 5 mL of DMF, and potassium carbonate (55 mg, 0.4 mmol) was added. After reacting at 80°C for 2 h, TLC indicated the reaction was complete. The reaction was quenched with water (20 mL), and the aqueous phase was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 4:1) to afford compound KT-021-1 (26 mg, 24% yield).

[0648] KT-022 was synthesized by referring to the KT-020 method.

[0649] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),9.09(t,J=6.0Hz,1H),7.87(d,J=7.9Hz,2H),7.69(d,J=7.8Hz,1H),7.54(s,1H),7.47-7.4 3(m,3H),7.15(d,J=8.5Hz,1H),6.90(s,1H),6.81(dd,J=8.5,2.1Hz,1H),5.10(dd,J=13.3,5.1Hz,1H),4.68(s,1H),4.59(d,J =5.8Hz,2H),4.37(dd,J=54.5,17.4Hz,2H),4.13(d,J=13.8Hz,1H),3.80–3.68(m,1H),3.60–3.37(m,3H),3.29–3.25(m,1H), 2.96–2.86(m,1H),2.79(t,J=10.0Hz,2H),2.73–2.54(m,3H),2.42–2.25(m,2H),2.20(s,3H),2.03–1.90(m,1H).ESI-MS(M+H) + :630.3.

[0650] The intermediate KT-022-1 corresponding to KT-022 was synthesized as follows:

[0651] Synthesis of compound KT-022-1

[0652] Compound 1-Boc-3-hydroxymethylpiperazine (1.05 g, 5.0 mmol) and methyl p-formylbenzoate (820 mg, 5.0 mmol) were dissolved in 20 mL of methanol, and a catalytic amount of acetic acid was added. After reacting at room temperature for 30 minutes, sodium cyanoborohydride (630 mg, 10.0 mmol) was added. After reacting at room temperature overnight, TLC indicated the reaction was complete. The reaction was quenched with water (60 mL), and the aqueous phase was extracted with dichloromethane (60 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 1:1) to afford compound KT-022-1 (1.25 g, 69% yield).

[0653] KT-034 was synthesized by referring to the synthesis method of KT-020

[0654] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),9.38(t,J=5.9Hz,1H),7.82(d,J=8.1Hz,1H),7.69(d,J=8.1Hz,1H), 7.55(s,1H),7.47(d,J=7.9Hz,1H),7.28-7.24(m,2H),7.20-7.15(m,3H),6.86–6.76(m,2H),5.08(dd,J =13.3,5.1Hz,1H),4.61(d,J=5.7Hz,2H),4.37(dd,J=54.7,17.4Hz,2H),3.51(s,2H),2.94-2.84(m,1H) ,2.80–2.73(m,2H),2.65–2.55(m,3H),2.44-2.31(m,1H),2.20(s,3H),2.04-1.94(m,1H).ESI-MS(M+H) + :541.3.

[0655] The intermediate KT-034-1 corresponding to KT-034 was synthesized as follows:

[0656] Synthesis of compound KT-034-1

[0657] Compound N-methyl-2-phenylethylamine (373 mg, 2.77 mmol), KT-020-1 (450 mg, 1.84 mmol), and N,N-diisopropylethylamine (593 mg, 4.6 mmol) were dissolved in 8 mL of acetonitrile. After reacting at 80°C overnight, TLC indicated the reaction was complete. The reaction was quenched by adding water (25 mL), and the aqueous phase was extracted with ethyl acetate (25 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 10:1) to afford compound KT-034-1 (300 mg, 54% yield).

[0658] Example 8

[0659] Synthesis of compound KT-024-1

[0660] 2-(3,4-Dichlorophenyl)ethanol (500 mg, 2.63 mmol) was dissolved in 12 mL of DCM, and Dess-Martin reagent (1.67 g, 3.95 mmol) was added portionwise under an ice bath. After 2 h of reaction at room temperature, TLC indicated completion of the reaction. The reaction solution was filtered, and the filtrate was added with aq. NaHCO₃ (30 mL). Extraction was performed with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 100:1–15:1) to afford compound KT-024-1 (390 mg, 78% yield).

[0661] Synthesis of compound KT-024

[0662] Compound KT-024-1 (390 mg, 2.06 mmol), KT-001-5 (830 mg, 2.0 mmol) and acetic acid (100 mg) were dissolved in 20 mL of methanol. After reacting at room temperature for 0.5 h, sodium cyanoborohydride (260 mg, 4.13 mmol) was added. After continuing the reaction overnight, TLC showed that the reaction was complete. After adding saturated brine (30 mL), the mixture was extracted with dichloromethane (35 mL*3). After the organic phases were combined, they were dried over anhydrous sodium sulfate, filtered, and the solvent was dried. The crude product was purified by column chromatography (eluent: dichloromethane: methanol = 20:1) to obtain compound KT-024 (160 mg, yield 13%). ESI-MS (M+H) + :579.2. 1H NMR (400MHz, DMSO) δ11.00(s,1H),9.20(t,J=6.0Hz,1H),8.09(s,1H),8.01(d,J=8. 0Hz,1H),7.82(d,J=7.9Hz,1H),7.54–7.47(m,2H),7.28(s,4H),7.21(dd,J=8.2,2. 0Hz,1H),5.14(dd,J=13.2,5.1Hz,1H),4.56–4.35(m,4H),3.73(s,2H),2.97–2.88( m,1H),2.81–2.69(n,4H),2.65–2.56(m,1H),2.46–2.37(m,1H),2.08–1.92(m,1H).

[0663] Synthesis of compound I-11

[0664] Compound KT-024 (160 mg, 0.28 mmol), Mc-Val-Cit-PAB-PNP (224 mg, 0.30 mmol), and lutidine (59 mg, 0.55 mmol) were dissolved in 18 mL of DMF, and HoBt (19 mg, 0.14 mmol) was added. After 48 h of reaction at room temperature, TLC indicated that the reaction was complete. 50 mL of water was added to quench the reaction. The precipitated solid was filtered, and the filter cake was rinsed with water. After drying the filter cake, compound I-11 (22 mg, 7% yield) was prepared using medium pressure. ESI-MS (M+H) + :1177.5. 1H NMR (400MHz, DMSO) δ11.01(s,1H),9.99(s,1H),9.20(t,J=5.6Hz,1H),8.11–8.06(m,2H),8.00(d,J=7.9Hz,1H),7.85–7.7 7(m,2H),7.63–7.53(m,2H),7.51–7.02(m,9H),6.99(s,2H),5.97(t,J=5.7Hz,1H),5.40(s,2H),5.14(dd,J=13.3,5.1Hz,1 H),5.04–4.89(m,2H),4.54–4.32(m,7H),4.23–4.14(m,1H),3.08–2.88(m,3H),2.82–2.69(m,2H),2.66–2.56(m,1H),2.4 4–2.33(m,2H),2.24–2.09(m,2H),2.07–1.91(m,3H),1.74–1.55(m,2H),1.53–1.33(m,6H),1.22–1.12(m,2H),0.83(dd,J= 12.5,6.8Hz,6H).

[0665] KT-025 was synthesized by referring to the synthesis method of KT-024.

[0666] 1 H NMR (400MHz, DMSO) δ11.01 (s, 1H), 9.23 (t, J = 5.9Hz, 1H), 8.12–7.97 (m, 3H), 7.94 –7.87(m,1H),7.82(d,J=7.9Hz,1H),7.78-7.75(m,1H),7.54–7.25(m,8H),5.14(d d,J=13.3,5.1Hz,1H),4.59–4.34(m,4H),3.83(s,2H),3.25-3.20(m,2H),2.92–2 .83(m,3H),2.69–2.55(m,1H),2.46–2.34(m,1H),2.07–1.90(m,1H).ESI-MS(M+H) + :560.3.

[0667] Example 9

[0668] Synthesis of compound KT-013-1

[0669] Methyl 4-bromomethylbenzoate (500 mg, 2.2 mmol) was dissolved in 15 mL of methanol and a 30% methylamine solution (6 mL) was added. After reacting at room temperature for 1 hour, TLC indicated the reaction was complete. Water (30 mL) was added and the mixture was extracted with dichloromethane (35 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 20:1) to obtain compound KT-013-1 (230 mg, 57% yield).

[0670] Synthesis of compound KT-013-1

[0671] Compound KT-013-1 (230 mg, 1.3 mmol) and DIPEA (660 mg, 5.1 mmol) were dissolved in 15 mL of acetonitrile, and 2-bromoacetophenone (310 mg, 1.5 mmol) was added. After reacting at 60°C for 2 h, TLC indicated the reaction was complete. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 4:1) to obtain compound KT-013-2 (250 mg, 65% yield).

[0672] Synthesis of compound KT-013-3

[0673] Compound KT-013-2 (250 mg, 0.8 mmol) was dissolved in 15 mL of methanol and sodium borohydride (48 mg, 1.3 mmol) was added under ice. After reacting at 0°C for 2 h, TLC indicated the reaction was complete. Water (20 mL) was added and the mixture was extracted with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 2:1) to obtain compound KT-013-3 (200 mg, 79% yield).

[0674] The synthesis operation of KT-013-4 and KT-013 refers to the preparation method of KT-017-4 and KT-017.

[0675] 1H NMR (400MHz, DMSO) δ10.97(s,1H),9.09(t,J=5.9Hz,1H),7.82(d,J=8.2Hz,2H),7.69(d,J=7.8Hz,1H),7. 54(s,1H),7.46(d,J=7.9Hz,1H),7.36–7.27(m,6H),7.26–7.19(m,1H),5.10(dd,J=13.3,5.1Hz,1H),4.74 (dd,J=7.6,5.1Hz,1H),4.58(d,J=5.9Hz,2H),4.37(dd,J=54.6,17.4Hz,2H),3.60(s,2H),2.96–2.84(m,1 H),2.65–2.53(m,2H),2.49–2.44(m,1H),2.43-2.32(m,2H),2.22(s,3H),2.05-1.95(m,1H).ESI-MS(M+H) + :541.3.

[0676] Example 10

[0677] Synthesis of compound KT-015-1

[0678] Compound 2-benzyloxy-1-ethylamine (30 mg, 0.2 mmol) was dissolved in 5 mL of DMF, and N,N-carbonyldiimidazole (34 mg, 0.2 mL) was added. After reacting at room temperature for 2 h, KT-001-6 (50 mg, 0.1 mmol) was added. After reacting at 0°C for 2 h, TLC indicated the reaction was complete. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (35 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 20:1) to obtain compound KT-015-1 (35 mg, 70% yield).

[0679] KT-015 synthesis operation refers to KT-019

[0680] 1H NMR (400MHz, DMSO) δ11.00(s,1H),9.19(t,J=5.9Hz,1H),8.08(s,1H),8.00(d,J=8.0Hz,1H),7.81(d,J=7. 9Hz,1H),7.30-7.24(m,4H),7.19-7.15(m,5H),6.38(t,J=5.5Hz,1H),5.14(dd,J=13.2,5.1Hz,1H),4.61(t ,J=5.4Hz,1H),4.56–4.32(m,6H),3.39(dd,J=11.8,6.1Hz,2H),3.29-3.24(m,2H),3.13(q,J=6.1Hz,2H),2 .97–2.86(m,1H),2.75–2.68(m,2H),2.66-2.55(m,1H),2.48–2.35(m,1H),2.06–1.97(m,1H).ESI-MS(M+H) + :598.3.

[0681] Example 11

[0682] Synthesis of compound KT-026-1

[0683] Dissolve 5-bromo-2-chloro-3-carboxaldehyde pyridine (250 mg, 1.14 mmol) in 5 mL of DMF and add methyl piperidine acetate (264 mg, 1.37 mL). After reacting at 80°C for 2 h, TLC indicated the reaction was complete. Add water (30 mL) and extract with ethyl acetate (35 mL x 3). Combine the organic phases and wash with saturated brine (10 mL x 3). Dry the organic phase over anhydrous sodium sulfate, filter, and spin-dry the solvent. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 5:1) to obtain compound KT-026-1 (197 mg, 50% yield).

[0684] Synthesis of compound KT-026-2

[0685] Compound KT-026-1 (197 mg, 0.58 mmol) was dissolved in 6 mL of methanol and sodium borohydride (33 mg, 0.87 mmol) was added under ice. After reacting at 0°C for 2 h, TLC indicated the reaction was complete. Water (20 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 5:1) to obtain compound KT-026-2 (190 mg, 97% yield).

[0686] The synthesis operation of KT-026-3 and KT-026 refers to the preparation method of KT-017-4 and KT-017.

[0687] 1 H NMR (400MHz, DMSO) δ10.97 (s, 1H), 10.26 (s, 1H), 8.21 (d, J = 2.5Hz, 1H), 8.00 (s, 1H), 7.86 (d, J=2.4Hz,1H),7.65(d,J=8.3Hz,1H),7.59(d,J=9.6Hz,1H),5.08(dd,J=13.1,5.0Hz,1H),4.4 7–4.23(m,4H),3.34–3.26(m,2H),2.96–2.83(m,1H),2.74(t,J=11.8Hz,2H),2.64-2.54(m,1 H),2.43–2.28(m,3H),2.04–1.93(m,2H),1.81-1.69(m,2H),1.43-1.30(m,2H).ESI-MS(M+H) + :570.3.

[0688] KT-028 was prepared by referring to the synthesis method of KT-026.

[0689] 1 H NMR (400MHz, DMSO) δ10.97 (s, 1H), 10.28 (s, 1H), 8.91 (dd, J = 4.1, 1.7Hz, 1H), 8 .51–8.38(m,2H),8.07(d,J=2.2Hz,1H),8.03-7.97(m,2H),7.82–7.75(m,1H), 7.73-7.64(m,2H),7.64–7.53(m,2H),5.28(t,J=5.4Hz,1H),5.08(dd,J=13.2, 5.1Hz,1H),4.55(d,J=5.1Hz,2H),4.37(dd,J=56.0,17.3Hz,2H),3.54-3.44(m, 2H),3.01–2.81(m,3H),2.66-2.55(m,1H),2.44–2.26(m,3H),2.06-1.93(m,2H),1.87-1.77(m,2H),1.52-1.40(m,2H).ESI-MS(M+H) + :619.3.

[0690] The intermediate KT-028-2 corresponding to KT-028 was synthesized as follows:

[0691] Synthesis of compound KT-028-1

[0692] Quinoline-8-boronic acid (870 mg, 5.0 mmol), KT-026-1 (1.7 g, 0.90 mmol) and potassium carbonate (2.07 g, 15.0 mmol) were dissolved in dioxane / water (20 mL / 5 mL), and Pd(dppf)Cl2 (366 mg, 0.5 mmol) was added thereto. Nitrogen was replaced three times, and after reacting at 90 ° C for 3 hours, TLC showed that the reaction was complete. The reaction solution was filtered, and the filtrate was diluted with ethyl acetate (60 mL). The organic phase was washed with saturated brine (20 ml * 3) and the solution was dried by spin drying. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain compound KT-028-1 (300 mg, yield 88%). Synthesis of compound KT-028-2

[0693] Compound KT-028-1 (780 mg, 2.0 mmol) was dissolved in 40 mL of methanol and sodium borohydride (152 mg, 4.0 mmol) was added under ice. After reacting at 0°C for 2 h, TLC indicated the reaction was complete. Water (60 mL) was added, and the mixture was extracted with ethyl acetate (60 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 1:1) to obtain compound KT-028-2 (640 mg, 82% yield).

[0694] KT-030 was synthesized by referring to the synthesis method of KT-026.

[0695] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),10.29(s,1H),8.59(d,J=5.6Hz,1H),8.46(d,J=2.3Hz,1H),8.13– 8.00(m,4H),7.86-7.78(m,2H),7.71–7.59(m,3H),5.37(t,J=5.4Hz,1H),5.08(dd,J=13.3,5.1Hz,1H ),4.56(d,J=5.0Hz,2H),4.35(dd,J=56.0,17.4Hz,2H),3.62-3.51(m,2H),2.96–2.82(m,3H),2.66–2 .56(m,1H),2.44-2.32(m,3H),2.07-1.96(m,2H),1.87-1.77(m,2H),1.53-1.35(m,2H).ESI-MS(M+H) + :619.4.

[0696] The intermediate KT-030-2 corresponding to KT-030 was synthesized as follows:

[0697] Synthesis of compound KT-030-1

[0698] Pinacol borate (2.35 g, 9.26 mmol), KT-026-1 (2.1 g, 6.18 mmol), and potassium acetate (1.51 g, 15.45 mmol) were dissolved in 20 mL of dioxane, and Pd(dppf)Cl2 (454 mg, 0.62 mmol) was added. The atmosphere was purged with nitrogen three times and allowed to react overnight at 90°C. TLC indicated the reaction was complete. The reaction solution was filtered, and the filtrate was diluted with ethyl acetate (60 mL). The organic phase was washed with saturated brine (20 mL x 3) and the solution was spin-dried to dryness. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain compound KT-030-1 (1.86 g, 77% yield).

[0699] Synthesis of compound KT-030-2

[0700] 1-Bromoisoquinoline (290 mg, 1.4 mmol), KT-030-1 (504 mg, 1.3 mmol), and potassium carbonate (449 mg, 15.0 mmol) were dissolved in dioxane / water (4 mL / 1 mL). Pd(dppf)Cl2 (95 mg, 0.62 mmol) was added. The atmosphere was replaced with nitrogen three times and the mixture was allowed to react overnight at 80°C. TLC indicated the reaction was complete. The reaction solution was filtered, and the filtrate was diluted with ethyl acetate (60 mL). The organic phase was washed with saturated brine (20 mL x 3) and the solution was dried by spin drying. The crude product was isolated and purified by column chromatography (petroleum ether:ethyl acetate = 3:1) to obtain compound KT-030-2 (408 mg, 81% yield).

[0701] Example 12

[0702] Synthesis of compound KT-027

[0703] Compound KT-026 (60 mg, 0.10 mmol) and palladium on carbon (5%, 10 mg) were dissolved in 5 mL of methanol. The reaction was allowed to proceed at room temperature for 2 hours under a hydrogen atmosphere. TLC indicated the reaction was complete. The reaction mixture was filtered, the filter cake rinsed with methanol, and the filtrate was spin-dried to dryness. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 15:1) to obtain compound KT-027 (8 mg, 16% yield).

[0704] 1H NMR (400MHz, DMSO) δ10.97(s,1H),10.27(s,1H),8.12(dd,J=4.8,1.9Hz,1H),8.01(s,1H),7.75(dd,J=7 .4,1.8Hz,1H),7.66(d,J=8.3Hz,1H),7.60(dd,J=8.3,1.6Hz,1H),6.98(dd,J=7.4,4.8Hz,1H),5.25(s,1 H),5.08(dd,J=13.3,5.1Hz,1H),4.50–4.22(m,4H),3.34–3.22(m,2H),2.97–2.81(m,1H),2.73(t,J=11. 6Hz,2H),2.64-2.54(m,1H),2.45-2.29(m,3H),2.05-1.92(m,2H),1.81-1.72(m,2H),1.45-1.32(m,2H).

[0705] ESI-MS (M+H) + :492.3.

[0706] Example 13

[0707] Synthesis of compound KT-029-1

[0708] Compound KT-028-2 (640 mg, 1.63 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (380 mg, 2.5 mmol) were dissolved in 20 mL of toluene, and diphenylphosphoryl azide (550 mg, 2.0 mmol) was added. After 3 h of reaction at room temperature, TLC indicated the reaction was complete. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated to obtain crude compound KT-029-1 (680 mg, crude product) which was used directly in the next reaction.

[0709] Synthesis of compound KT-029-2

[0710] Compound KT-029-1 (680 mg, 1.63 mmol), di-tert-butyl dicarbonate (540 mg, 2.5 mmol), and palladium on carbon (5%, 50 mg) were dissolved in 10 mL of methanol. The reaction was allowed to proceed at room temperature for 5 hours under a hydrogen atmosphere. TLC indicated the reaction was complete. The reaction mixture was filtered, the filter cake rinsed with methanol, and the filtrate was dried by rotary evaporation. The crude product was purified by column chromatography (eluent: petroleum ether:ethyl acetate = 1:1) to obtain compound KT-029-2 (350 mg, 44% yield).

[0711] The synthesis operation of KT-029-3 and KT-029-4 refers to the preparation method of KT-017-4 and KT-017.

[0712] Synthesis of compound KT-029

[0713] Compound KT-029-4 (108 mg, 0.15 mmol) was dissolved in 5 mL of ethyl acetate and HCl / dioxane (4 M, 5 mL) was added. After 2 hours of reaction at room temperature, TLC indicated the reaction was complete. The reaction solution was spin-dried. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 10:1) to obtain compound KT-029 (43 mg, 47% yield).

[0714] 1 H NMR (400MHz, DMSO) δ10.33(s,1H),8.91(dd,J=4.1,1.7Hz,1H),8.50(d,J=2.2Hz,1H),8.44(dd,J=8.3,1.7Hz,1 H),8.12(d,J=2.0Hz,1H),8.05–7.96(m,2H),7.81(dd,J=7.1,1.2Hz,1H),7.74–7.64(m,2H),7.64–7.54(m,2H) ,5.07(dd,J=13.3,5.1Hz,1H),4.36(dd,J=56.0,17.4Hz,2H),3.94(s,2H),3.54-3.44(m,2H),2.97-2.80(m,3H ),2.65–2.56(m,1H),2.46–2.27(m,3H),2.07–1.92(m,2H),1.87-1.77(m,2H),1.55-1.41(m,2H).ESI-MS(M+H) + :618.4.

[0715] Example 14

[0716] Synthesis of compound KT-031-1

[0717] 5-Bromo-2-fluoro-3-hydroxypyridine (500 mg, 2.6 mmol) and benzyl 2-bromoethyl ether (840 mg, 0.3 mmol) were dissolved in 15 mL of DMF, and cesium carbonate (1.7 g, 5.2 mmol) was added. After reacting at 120°C for 2 h, TLC indicated the reaction was complete. Water (60 mL) was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (60 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 10:1) to afford compound KT-031-1 (800 mg, 94% yield).

[0718] The synthesis procedures of KT-031-2, KT-031-3, KT-031-4 and KT-031-5 refer to the preparation methods of KT-026-1, KT-028-1, KT-017-4 and KT-017.

[0719] Prepare KT-031 by referring to the synthesis method of KT-019

[0720] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),10.27(s,1H),8.92(dd,J=4.1,1.8Hz,1H),8.43(dd,J=8.3,1.7Hz,1H),8.09(d,J= 1.8Hz,1H),8.02-7.97(m,2H),7.82(dd,J=7.1,1.3Hz,1H),7.74–7.47(m,5H),5.08(dd,J=13.3,5.1Hz,1H),4.85(br s,1H),4.36(dd,J=56.2,17.4Hz,2H),4.17-4.08(m,2H),4.06(t,J=4.9Hz,2H),3.81-3.72(m,2H),2.97–2.85(m,1H),2.84 -2.74(m,2H),2.65-2.56(m,1H),2.44–2.31(m,3H),2.07-1.95(m,2H),1.83-1.72(m,2H),1.50-1.36(m,2H).ESI-MS(M+H) + :649.6.

[0721] Example 15

[0722] Synthesis of compound KT-032-1

[0723] Compound KT-031-3 (2 g, 3.9 mmol) was dissolved in 40 mL of dichloromethane and a 1 M solution of BCl₃ (11.7 mL) was added under ice-cooling. The reaction was allowed to proceed at room temperature for 1 h, and TLC indicated completion. Methanol (10 mL) was added to quench the reaction, and the solvent was evaporated. The crude product was purified by column chromatography (mobile phase: dichloromethane:methanol = 10:1) to afford compound KT-032-1 (1.5 g, 91% yield).

[0724] Synthesis of compound KT-032-2

[0725] Compound KT-032-1 (1.4 g, 3.3 mmol) and triethylamine (670 mg, 6.6 mmol) were dissolved in 20 mL of dichloromethane. Methanesulfonyl chloride (570 mg, 4.9 mmol) was added under ice-cooling. The reaction was allowed to react at room temperature for 3 h, and TLC indicated completion. After quenching the reaction with water (10 mL), the aqueous phase was extracted with dichloromethane (40 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 1:1) to obtain compound KT-032-2 (1.15 g, 69% yield).

[0726] Synthesis of compound KT-032-3

[0727] Compound KT-032-2 (1.15 g, 2.3 mmol) was dissolved in 20 mL of DMF, and sodium azide (200 mg, 3 mmol) was added. After reacting at 60°C overnight, TLC indicated the reaction was complete. The reaction was quenched with water (30 mL), and the aqueous phase was extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated. The crude product was purified by column chromatography (mobile phase: petroleum ether:ethyl acetate = 1:1) to obtain compound KT-032-3 (1.03 g, 100% yield).

[0728] The synthesis operation of KT-032-4 refers to KT-029-2, and the synthesis operation of KT-032-5 and KT-032-6 refers to KT-026-3 and KT-026

[0729] KT-032 was synthesized by referring to the synthesis method of KT-029.

[0730] 1H NMR (400MHz, DMSO) δ10.32(s,1H),8.91(d,J=2.6Hz,1H),8.43(d,J=7.5Hz,1H),8.11(s,1H),8.06– 7.94(m,2H),7.81(d,J=6.9Hz,1H),7.73–7.64(m,2H),7.63–7.55(m,3H),5.07(dd,J=13.2,5.1Hz,1 H),4.36(dd,J=56.4,17.2Hz,2H),4.14–3.98(m,4H),3.13-2.97(m,2H),2.93–2.73(m,3H),2.66-1. 55(m,1H),2.45–2.27(m,3H),2.08–1.93(m,2H),1.84-1.73(m,2H),1.50-1.33(m,2H).ESI-MS(M+H) + :648.4.

[0731] Example 16

[0732] The synthesis method of KT-042-1 is the same as that of KT-004 (except that S-acetylthioacetic acid is used instead of glycolic acid).

[0733] Synthesis of compound KT-042

[0734] Compound KT-042-1 (50 mg, 0.074 mmol) was dissolved in 5 mL of tetrahydrofuran and diluted hydrochloric acid (1 M, 1 mL) was added. After reacting at 50°C overnight, TLC indicated completion of the reaction. Aq. NaHCO₃ (10 mL) was added to the reaction solution, which was then extracted with dichloromethane (10 mL x 3). The organic phases were combined, dried, and the solvent was evaporated. The crude product was purified by column chromatography (eluent: dichloromethane:methanol = 15:1) to obtain compound KT-042 (1 mg, 2% yield). 1H NMR(400MHz,DMSO)δ11.02(s,1H),9.23(t,J=6.0Hz,1H),8.16–7.96(m,3H),7.94-7.87(m,1 H),7.84-7.74(m,2H),7.56–7.26(m,6H),7.26–7.17(m,2H),5.14(dd,J=13.3,5.1Hz,1H),4. 58(d,J=9.9Hz,2H),4.53–4.32(m,4H),3.57–3.43(m,2H),3.33–3.28(m,2H),3.22–3.14(m,1 H),2.98–2.77(m,2H),2.65-2.56(m,1H),2.43-2.36(m,1H),2.05-1.95(m,1H).ESI-MS(M+H) + :635.4.

[0735] Example 17

[0736] KT-041 synthesis reference KT-017

[0737] 1 H NMR (400MHz, DMSO) δ10.97(s,1H),9.12(t,J=6.0Hz,1H),7.88(d,J=8.2Hz,2H),7.72-7.68( m,2H),7.54(s,1H),7.49–7.39(m,3H),6.97–6.87(m,2H),5.10(dd,J=13.3,5.1Hz,1H),4.5 9(d,J=5.8Hz,2H),4.37(dd,J=54.5,17.3Hz,2H),3.58(s,2H),3.33-3.28(m,8H),2.95–2.8 2(m,1H),2.63–2.54(m,1H),2.51(s,3H),2.44-2.31(m,1H),2.02–1.95(m,1H).ESI-MS(M+H) + :628.4.

[0738] Biological activity assay

[0739] 1. Inhibitory activity of compounds on HL60 cells

[0740] Activity test method:

[0741] 1. Cell Plating

[0742] HL60 cells in the logarithmic growth phase were counted and evenly plated in a 96-well transparent bottom white plate, with 20,000 cells per well and 100 μL per well.

[0743] 2. Cell Dosing

[0744] Weigh a certain amount of compound and dilute it to a 10mM stock solution with DMSO. Take the appropriate cell culture medium and dilute the drug to the desired experimental concentration, gently shaking to mix. Add 50μL of the serial dilutions of compound to each well of the plated cells. For the control group, add 50μL of 0.1% DMSO and gently shake to mix. Place in a cell culture incubator and incubate for 3 days.

[0745] 3. CTG test

[0746] 3.1 Add CellTiter-Glo in advance TM The (CTG) reagent was taken out of the -20°C refrigerator and equilibrated to room temperature in the dark.

[0747] 3.2 Remove the 96-well plate and examine it under a microscope to check the growth status.

[0748] 3.3 Cover the bottom of the taken-out 96-well plate with white paper, then wrap it with tin foil and shake it at 37°C and 300 rpm for 10 minutes.

[0749] 3.4 Add 50ul CTG detection reagent to each well, detect the luminescence signal with a microplate reader, and calculate the inhibition rate. Calculate the IC value of the compound using XLfit software. 50 The inhibitory activity of HL60 cells was evaluated by ELISA. The experimental results are shown in Table 1.

[0750] Table 1 Inhibitory activity of compounds on HL60 cells

[0751] 2. Protein degradation experiment

[0752] 1. Experimental Materials

[0753] Cell culture conditions: All cells used in the examples were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. Human acute promyelocytic leukemia cells (HL60) were cultured in RPMI-1640 (meilunbio, MA0215) supplemented with 20% FBS (manufacturer: BI, catalog number: 04-001-1ACS) and 1% penicillin / streptomycin (manufacturer: Hyclone, catalog number: SH40003.01). Cell culture conditions were 5% CO₂ and 37% humidity. When the confluence reached approximately 80%, the cells were passaged at a 1:3 ratio.

[0754] 2. Cell Drug Treatment and Protein Extraction

[0755] 2.1 Cell treatment

[0756] When HL60 cells were in the exponential growth phase, they were plated into 6-well plates at a rate of 1 × 10 6 cells, the compound of the present invention was added to culture the cells, and proteins were extracted after drug treatment for 6 hours.

[0757] 2.2 Cell protein extraction

[0758] Collect the cells in a 1.5 mL centrifuge tube, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add 1 ml of PBS to wash the cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add 100 μL of RIPA lysis buffer (Solarbio, product number R0010) (containing 100 μM PMSF) to each tube, mix thoroughly and let stand on ice for 30 minutes, then centrifuge at 12000 rpm for 20 minutes at 4°C. Take the supernatant for Western blotting (WB) experiments. Samples can be stored at -80°C.

[0759] 2.3 Protein concentration determination

[0760] Use the BCA protein concentration assay kit (from Thermo Fisher, catalog number 23225) to prepare the BSA standard assay solution and the supernatant for western blot obtained in step 2.2 according to Table 2 below (the supernatant can be diluted for detection). Load the sample into a 96-well plate, fill each well with PBS to 20 μl, then add 200 μl of BCA working solution (prepared according to the kit) to each well. Mix well, incubate at 60°C for 10 min, and measure absorbance at 562 nm. Record the readings and create a standard curve using a gradient of standard concentrations. Substitute the sample absorbance into the curve to calculate the protein concentration of the sample.

[0761] Table 2 Preparation of protein quantitative standards

[0762] 3 Western blotting experimental standard process

[0763] 3.1 Protein denaturation: Take RIPA protein lysate, add 5× Loading Buffer (SDS, glycerol, bromophenol blue, TRIS) (purchased from Solarbio, product number P1040), and denature at 100°C for 5 min.

[0764] 3.2 Sample loading and electrophoresis: A 10% 15-well precast gel (GenScript, Cat. No. M00666) and corresponding electrophoresis buffer (GenScript, Cat. No. M00138) were used. A protein ladder (purchased from Thermo, Cat. No. 26617) and the same amount of protein sample were loaded into each well, and electrophoresis was performed at 200 V for 30 min.

[0765] 3.3 Blocking: After removing the gel, cut off the excess portion and transfer to a PVDF membrane (Millipore, Catalog No. ISEQ00010) by wet transfer (PVDF membrane needs to be activated with methanol for 1 min before use) at 300 mA for 2 h. A large amount of heat is generated during the transfer process, so an ice box is required to cool it down.

[0766] 3.4 Blocking: Place the transferred PVDF membrane in 5% (w / w) skim milk and shake at room temperature for 1 hour to block.

[0767] 3.5 Incubation with primary antibodies: Cut the PVDF membrane according to the molecular weight indicated on the marker and incubate with primary antibodies against c-myc (purchased from abcam, product number ab32072), GSPT1 (purchased from abcam, product number ab234433), and GAPDH (purchased from CST, product number #97166), respectively. The antibodies were diluted at a ratio of 1:1000 with TBST buffer (a solution prepared with TRIS, KCl, and NaCl, adjusted to pH 7.4 with hydrochloric acid, and Tween 20 was added). Block the membrane overnight at 4°C on a shaker.

[0768] 3.6 Incubation with secondary antibodies: After incubation with primary antibodies, the PVDF membrane was washed three times with TBST on a shaker for 10 min each time. After washing, the membrane was placed in (Anti-mouse IgG, HRP-linked Antibody (purchased from CST, catalog number #7076) or Anti-rabbit IgG, HRP-linked Antibody (purchased from CST, catalog number #7074)) on a shaker and incubated at room temperature for 1 h.

[0769] 3.7 Membrane washing and exposure: After incubation with the secondary antibody, the membrane was placed in TBST and washed on a shaker three times for 10 minutes each time. After washing, the enhanced chemiluminescence (ECL) method was used to display the intensity of the chemical light.

[0770] Protein degradation in these cells was tested using the aforementioned method, and the results are shown in Figure 1. The Blank group represents a DMSO blank control group without the test compound. Figure 1 demonstrates that compounds KT-004 and KT-002 can essentially completely degrade c-Myc and GSPT1 proteins in HL60 cells at relatively low concentrations (approximately 3 nM to 10 nM).

[0771] Summary of technical effects: The compounds of the present invention have excellent degradation capabilities for tumorigenic proteins in various tumor cells, such as degrading c-Myc and GSPT1 proteins in HL60 tumor cells. In addition, they can also degrade any one or more proteins including N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7 in other tumor cells, including c-Myc. Thus, they can be used to prevent, alleviate or treat diseases related to high expression of any one of the above-mentioned proteins (such as c-Myc) or multiple c-Myc proteins, such as cancer, cardiovascular and cerebrovascular diseases, viral infections and other diseases. The degradation effects of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7 proteins are precise and significant.

[0772] The content of the present invention merely illustrates some specific embodiments for which protection is sought, wherein the technical features described in one or more technical solutions may be combined with any one or more technical solutions, and these technical solutions obtained by combination are also within the scope of protection of this application, just as these technical solutions obtained by combination have been specifically described in the disclosure of the present invention.

Claims

1. The compound represented by formula (I) and its pharmaceutically acceptable salts, solvent compounds, stereoisomers, isotopes and prodrugs thereof: in, R1 is selected from: a (CH2) a -、R a (CH2) a C(=O)-、R a (CH2) a NHC(=O)-、R a (CH2) a OC(=O)- or R a (CH2) a S(=O)2-, the "CH2" is optionally substituted by one or more R9, or is optionally substituted by -CH2CH2-, the "NH" is optionally substituted by R 14 replace; Q is selected from: -NR2-, -O-, R2 is selected from: hydrogen, R b -、R b C(=O)-、R b S(=O)2-、R 14 ; Ring A represents a heterocycloalkyl group containing at least one N atom as a heteroatom, which is connected to T or R1 via the N atom, and Ring A is optionally substituted by one or more groups selected from R9; R a , R b Selected from: C1-C8 alkyl, C3-C 10 Cycloalkyl, C3-C 10 Bridged ring group, -NR 11 R 12 、C3-C 10 Any containing O, S, SO2, N or NHC(=O)R 22 The C1-C8 alkyl group may be a heterocyclic group, an aryl group, a heteroaryl group, a fused arylcycloalkyl group, a fused arylheterocyclic group, a fused heteroarylcycloalkyl group, a fused heteroarylheterocyclic group, an aryl-aryl group, an aryl-heteroaryl group, a heteroaryl-aryl group, a heteroaryl-heteroaryl group, an aryl-alkyl group, a heteroaryl-alkyl group, an aryl-cycloalkyl group, an aryl-heterocyclic group, a cycloalkyl-heterocyclic group, a heterocyclic group-heterocyclic group, and any two CCs in the C1-C8 alkyl group may be inserted with a group selected from the group consisting of -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, -NHS(=O)2-, and R a Optionally substituted with one or more R9, R b Optionally one or more R 10 replace; T, U, and Z are independently selected from: chemical bonds, N, O, carbonyl, C1-C6 alkylene, C3-C 10 Cycloalkylene, arylene, heteroarylene, heterocyclylene, wherein the alkylene, cycloalkylene, arylene, heteroarylene, heterocyclylene is optionally substituted by one or more R9; Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-O(CH2) b -、-NR2(CH2) b -, the "CH2" is optionally substituted by one or more R9, or is optionally substituted by -CH2CH2-, the "NH" is optionally substituted by R 14 replace; L is selected from: -(CR7R8) o -, -C(=O)-; R3-R5, R7-R9 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, hydroxyl, thiol, nitro, -R 21 N(R 22 )R 22 , -R 21 C(=O)R 22 , -R 21 NHC(=O)R 22 , -R 21 C(=O)NHR 22 , -R 21 C(=O)OR 22 , -R 21 OC(=O)R 22 , -R 21 S(=O)2R 22 , -R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclic group containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclic group is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; when R3-R5, R7-R9 are multiple, any two adjacent groups can be combined to form a ring; R 10 Selected from: hydrogen, halogen, cyano, amino, nitro, -R 21 C(=O)R 22 , -R 21 NHC(=O)R 22 , -R 21 C(=O)NHR 22 , -R 21 C(=O)OR 22 , -R 21 OC(=O)R 22 , -R 21 S(=O)2R 22 , -R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclic group containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclic group is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; when R 10 In the case of multiple, any two adjacent ones can combine to form a ring; R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-C(=O)R n 、-C(=O)OR n 、-OC(=O)R n 、-NR m R n 、-C(=O)NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-S(=O)2R n 、-S(=O)2NR m R n 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; R n Selected from: C1-C8 alkyl substituted by hydroxyl, thiol or amino, any two CCs in the C1-C8 alkyl may be inserted with a group selected from -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, -NHS(=O)2-, and the C1-C8 alkyl may be substituted by 1-3 groups selected from halogen, cyano, amino, nitro or C1-C3 alkoxy; R m Independently selected from: hydrogen, C1-C8 alkyl, any two CCs in the C1-C8 alkyl may be inserted with a group selected from -O-, -S-, -C(=O)-, -C(=O)O-, -OC(=O)O-, -S(=O)-, -S(=O)2-, -NH-, -NHC(=O)-, -NHC(=O)NH-, -NHS(=O)2-, and the C1-C8 alkyl may be substituted with 1-3 groups selected from halogen, hydroxyl, cyano, amino, nitro or C1-C3 alkoxy; R6 is selected from the group consisting of: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered alkyl containing 1-3 heteroatoms heteroaryl or a 3-10 membered heterocyclic group containing 1-3 heteroatoms, wherein the alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic group is optionally substituted by 1-3 groups selected from halogen, hydroxyl, cyano, amino, nitro, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 ,-C(=O)NHR 23 , C1-C3 alkyl, C 1- C3 alkoxy or -OP(=O)(OM)2 group substitution; M is independently selected from: hydrogen, C1-C4 alkyl; R 11 , R 12 Each is independently selected from: hydrogen, C1-C4 alkyl, aryl, aryl-alkyl; R 21 Selected from: chemical bonds, C1-C4 alkylene; R 22 , R 23 Each is independently selected from: hydrogen, C1-C4 alkyl, aryl, aryl-alkyl, wherein the C1-C4 alkyl, aryl, aryl-alkyl is optionally substituted by a group selected from halogen, hydroxyl, and amino; a is selected from: 0, 1, 2, 3, 4 or 5; b is selected from: 0, 1, 2, 3, 4 or 5; n is selected from: 0, 1, 2 or 3; m is selected from: 0, 1, 2, 3 or 4; oSelected from: 1 or 2; The compound represented by the formula (I) is not: Preferably, the compound represented by formula (I) contains at least one selected from R 13 or R 14 The group.

2. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R1 is selected from: a C(=O)-、R a CH2C(=O)-、R a CH2CH2C(=O)-、R a -、R a CH2-、R a CH2CH2-、R a NHC(=O)-、R a CH2NHC(=O)-、R a CH2CH2NHC(=O)-、R a OC(=O)-、R a CH2OC(=O)-、R a CH2CH2OC(=O)-、R a S(=O)2-、R a CH2S(=O)2-、R a CH2CH2S(=O)2-, wherein the "CH2" is optionally substituted by one or more R9, or optionally substituted by -CH2CH2-, wherein the "NH" is optionally substituted by R 14 replace.

3. The compound according to claim 2 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: R1 is selected from: R a C(=O)-, R a CHR9C(=O)-, R a CHR9CH2C(=O)-, R a CHCHR9C(=O)-, R a -, R a CHR9-, R a CHR9CH2-, R a CHCHR9-, R a NR 14 C(=O)-, R a CHR9NHC(=O)-, R a CHNR 14 C(=O)-, R a CHR9CH2NHC(=O)-, R a CH2CHR9NHC(=O)-, R a CH2CH2NR 14 C(=O)-, R a OC(=O)-, R a CHR9OC(=O)-, R a CHR9CH2OC(=O)-, R a CH2CHR9OC(=O)-, R a CHR9S(=O)2-, R a CHR9CH2S(=O)2-, R a CH2CHR9S(=O)2-.

4. The compound according to claim 2 or 3 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R9 is selected from: hydrogen, C1-C4 alkyl, -R 21 N(R 22 )R 22 , -R 21 C(=O)R 22 , R 13 ; The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ; The R 14 Selected from: R n 、-C(=O)R n ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

5. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R a is selected from the group consisting of phenyl, naphthyl, carbazolyl, 1-azacarbazolyl, 2-azacarbazolyl, 1,8-diazacarbazolyl, indolyl, 7-azaindolyl, 2,3-dihydroindolyl, 2,3-dihydro-7-azaindolyl, phenoxazinyl, fluorenyl, quinolyl, isoquinolyl, naphthyridinyl, tetrahydronaphthyridinyl, tetrahydroquinolyl, pyrimidinyl, pyridinyl, quinolyl-pyridinyl, triazolyl, bicyclo[1.1.1]pentanyl, norbornyl, and adamantyl; preferably, R a Optionally substituted with one or more R9 selected from hydrogen, R 13 , halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

6. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R a Selected from: isoquinolyl-pyridyl; preferably, the R a Optionally substituted with one or more R9 selected from hydrogen, R 13 , halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl, naphthyl.

7. The compound according to claim 5 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R a Selected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazole-9-yl, 1-azacarbazole-9-yl, 2-azacarbazole-9-yl, 1,8-diazacarbazole-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazine-10-yl, fluorene-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, -yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5-(8-quinolin-yl)-pyridin-2-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl; preferably, R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphthyl-1-yl, naphthyl-2-yl.

8. The compound according to claim 6 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R a Selected from: 5-(1-isoquinolin-yl)-pyridin-2-yl; preferably, R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphthyl-1-yl, naphthyl-2-yl.

9. The compound according to any one of claims 5 to 8 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m Preferably, the R 13 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

10. The compound according to claim 9 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R9 is selected from: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, thiol, amino, -C(=O)CH3, C(=O)CH2CH3, C(=O)CH2CH2CH3, -CH2CH2N(CH3)2, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -OCH2OH, -OCH2CH2OH, -OCH2CH2CH2OH, -OCH2NH2, -OCH2CH2NH2, -OCH2CH2CH2NH2, -OCH2SH, -OCH2CH2SH, -OCH2CH2CH2SH, -NHCH2OH, -NHCH2CH2OH, -NHCH2CH2 CH2OH, -NHCH2NH2, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2SH, -NHCH2CH2SH, -NHCH2CH2CH2SH, -N(CH3)CH2OH, -N(CH3)CH2CH2OH, -N( CH3)CH2CH2CH2OH, -N(CH3)CH2NH2, -N(CH3)CH2CH2NH2, -N(CH3)CH2CH2CH2NH2, -N(CH3)CH2SH, -N(CH3)CH2CH2SH, -N(CH3)CH2CH2CH2S H, -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(COCH3)CH2NH2, -N(COCH3)CH2CH2NH2, -N(COCH3)CH2CH2CH2NH2, -N(COCH3)CH2SH, -N(COCH3)CH2CH2SH, -N(COCH3)CH2CH2CH2SH -N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH, -N( SO2CH3)CH2NH2, -N(SO2CH3)CH2CH2NH2, -N(SO2CH3)CH2CH2CH2NH2, -N(SO2CH3)CH2SH, -N(SO2CH3)CH2CH2SH, -N(SO2CH3)CH2CH2CH2SH.

11. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R a Selected from the following groups:

12. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R a Selected from the following groups:

13. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8alkyl or -S(=O)2C1-C8alkyl, the C1-C8alkyl, C3-C 10 Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl is optionally substituted by one or more R9, wherein R9 is selected from: hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy or aryl; preferably, R2 is selected from: R 14 .

14. The compound according to claim 13 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

15. The compound according to claim 14 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C (=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH , -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2S H, -C(=O)OCH2CH2CH2SH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O) NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, - S(=O)2CH2CH2NH2, -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH , -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2 CH2NH2, -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

16. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: Said Select one of the following structures: wherein each R9 is independently selected from: hydrogen, R 13 , halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy; Each a1 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, each a2 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, 8, each a3 is independently selected from: 0, 1, 2, 3, 4, 5, 6, 7, each a4 is independently selected from: 0, 1, 2, 3, 4, 5, 6, each a5 is independently selected from: 0, 1, 2, 3, 4, 5.

17. The compound according to claim 16 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; The R n Selected from: R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2 or -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

18. The compound according to claim 16 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: Said Select one of the following structures:

19. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The T and Z are independently selected from: a chemical bond, a carbonyl group, a C1-C6 alkylene group or a C3-C 10 Cycloalkylene, the C1-C6 alkylene, C3-C 10 The cycloalkylene group is optionally substituted with one or more R9.

20. The compound according to claim 19 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The T and Z are independently selected from: a chemical bond, a carbonyl group, a methylene group, a 1,2-ethylene group, a 1,1-cyclopropylene group or a 2,2-propylene group, and the methylene group, the 1,2-ethylene group, the 1,1-cyclopropylene group is optionally substituted by one or more R9.

21. The compound according to claim 19 or 20, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R9 is selected from: hydrogen, hydroxyl, thiol, amino, -R 21 N(R 22 )R 22 , -R 21 C(=O)R 22 , R 13 , C1-C6 alkyl or C3-C8 cycloalkyl; The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ; The R n Selected from: R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

22. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The U is selected from: C1-C6 alkylene, C3-C 10 Cycloalkylene, arylene or heteroarylene, wherein the alkylene, cycloalkylene, arylene or heteroarylene is optionally substituted by one or more R9; preferably, U is selected from: C2-C6 alkylene, C5-C6 cycloalkylene, C6-C 10 Arylene, 5-6 membered monocyclic heteroarylene, the alkylene, cycloalkylene, arylene, heteroarylene are optionally substituted by one or more R9.

23. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The U is selected from: 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,3-cyclopentylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,5-pyridylene, 2,5-pyrimidylene, 2,5-thiazolylene or 2,4-oxazolylene, and the 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,3-cyclopentylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,5-pyridylene, 2,5-pyrimidylene, 2,5-thiazolylene and 2,4-oxazolylene are optionally substituted with one or more R9.

24. The compound according to claim 22 or 23 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R9 is selected from: hydrogen, amino, hydroxyl, thiol, -R 21 N(R 22 )R 22 , -R 21 C(=O)R 22 , R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy; The R 13 Selected from: hydroxyl, amino, thiol, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

25. The compound according to claim 24 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R9 is selected from the group consisting of: F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, hydroxyl, thiol, amino, -C(O)CH3, C(O)CH2CH3, C(O)CH2CH2CH3, -CH2CH2N(CH3)2, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -OCH2OH, -OCH2CH2OH, -OCH2CH2OH, -O CH2CH2CH2OH, -OCH2NH2, -OCH2CH2NH2, -OCH2CH2CH2NH2, -OCH2SH, -OCH2CH2SH, -OCH2CH2CH2SH, -NHCH2OH, -NHCH2CH2OH, -NHCH2CH2CH 2OH, -NHCH2NH2, -NHCH2CH2NH2, -NHCH2CH2CH2NH2, -NHCH2SH, -NHCH2CH2SH, -NHCH2CH2CH2SH, -N(CH3)CH2OH, -N(CH3)CH2CH2OH, -N(CH 3)CH2CH2CH2OH, -N(CH3)CH2NH2, -N(CH3)CH2CH2NH2, -N(CH3)CH2CH2CH2NH2, -N(CH3)CH2SH, -N(CH3)CH2CH2SH, -N(CH3)CH2CH2CH2SH , -N(COCH3)CH2OH, -N(COCH3)CH2CH2OH, -N(COCH3)CH2CH2CH2OH, -N(COCH3)CH2NH2, -N(COCH3)CH2CH2NH2, -N(COCH3)CH2CH2CH2NH2, - N(COCH3)CH2SH, -N(COCH3)CH2CH2SH, -N(COCH3)CH2CH2CH2SH-N(SO2CH3)CH2OH, -N(SO2CH3)CH2CH2OH, -N(SO2CH3)CH2CH2CH2OH, -N(S O2CH3)CH2NH2, -N(SO2CH3)CH2CH2NH2, -N(SO2CH3)CH2CH2CH2NH2, -N(SO2CH3)CH2SH, -N(SO2CH3)CH2CH2SH, -N(SO2CH3)CH2CH2CH2SH.

26. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The U is selected from the following groups:

27. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The -TUZ- together form a group selected from the following:

28. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The -TUZ- groups together form a group selected from the following: C1-C6 alkylene; preferably, the -TUZ- groups together form a group selected from the following: C1 alkylene, 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene.

29. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The Y is selected from: a chemical bond, -C(=O)NH-, -C(=O)NHCH2-, -C(=O)NHCH2CH2-, -C(=O)NHCH2CH2CH2-, -NHC(=O)-, -NHC(=O)CH2-, -NHC(=O)CH2-, -NHC(=O)CH2CH2-, -NHC(=O)CH2CH2-, -NHC(=O)CH2CH2CH2-, -O-, -OCH2-, -OCH2CH2-, -OCH2CH2CH2-, -NR2-, -NR2CH2-, -NR2CH2CH2-, -NR2CH2CH2-.

30. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The Y is selected from: chemical bond, -NR 14 C(=O)-, -C(=O)NR 14 -、-C(=O)NR 14 CH2-, -C(=O)NHCHR9-, -NR 14 C(=O)CH2-, -NHC(=O)CHR9-, -O-, -OCHR9-, -OCHR9CH2-, -OCH2CHR9-, -NR2-, -NR2CH2-, -NHCHR9-; The R9 is selected from: hydrogen, C1-C4 alkyl, -R 21 N(R 22 )R 22 , -R 21 C(=O)R 22 , R 13 ; The R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n ; The R 14 Selected from: R n 、-C(=O)R n ; The R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, aryl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8alkyl or -S(=O)2C1-C8alkyl, the C1-C8alkyl, C3-C 10 Cycloalkyl, aryl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl is optionally substituted by one or more R9, wherein R9 is selected from hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy or aryl; wherein R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

31. The compound according to claim 30 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)C H2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O )OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH, -C(=O)NHCH2OH, -C(=O )NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2C H2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2, -S(=O)2C H2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2O H, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

32. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The L is selected from: -CH2-, -CH2CH2-, -C(=O)-, and -CH(OH)-.

33. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R3-R5 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl are optionally substituted by 1-3 groups selected from halogen, C1-C3 alkyl or C1-C3 alkoxy respectively; when R3-R5 are multiple, any two adjacent groups can be combined to form a ring.

34. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R6 is selected from: hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, and the alkyl and cycloalkyl are optionally substituted by 1-3 groups selected from halogen, hydroxyl, cyano, amino, -C(=O)OR 23 、-OC(=O)R 23 、-NHC(=O)R 23 ,-C(=O)NHR 23 or -OP(=O)(OM)2; preferably, R6 is selected from: hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, -C1-C4 alkylene OC(=O)R 23 、-C1-C4 alkylene C(=O)OR 23 、-C1-C4 alkylene OP(=O)(OH)2;R 23 Selected from: hydrogen, C1-C4 alkyl, the C1-C4 alkyl is optionally substituted by 1-3 groups selected from hydroxyl and amino.

35. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (I-1) or formula (I-2): Wherein, R1, R3-R6, Q, T, U, Z, Y, L, n, and m are as defined above.

36. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (II) or formula (III): Wherein, R1, R3-R6, Q, T, U, Z, Y, L, n, and m are as defined above.

37. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (IV) or formula (V): Among them, the R a CH2C(=O)NH-、-C(R 94 )(R 95 )NHC(=O)-、-C(R 94 )(R 95 )C(=O)NH-"NH" is optionally replaced by R 14 replace; R a , R 14 , L is defined as above; R 91 -R 95 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 , -R 21 NHC(=O)R 22 , -R 21 C(=O)NHR 22 , -R 21 C(=O)OR 22 , -R 21 OC(=O)R 22 , -R 21 S(=O)2R 22 , -R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; R 92 -R 94 Any two adjacent ones can combine to form a ring.

38. The compound according to claim 37 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R 91 Selected from: hydrogen, R 13 , halogen, cyano, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C3-C8 cycloalkyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms or 3-10 membered heterocyclic group containing 1-3 heteroatoms, the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclic group is optionally substituted by 1-3 groups selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; preferably, the R 91 Selected from: hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m More preferably, the R 91 Selected from: hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ; The R 92 -R 94 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 92 -R 94 Any two adjacent ones of can combine to form a cycloalkyl group; preferably, the R 92 -R 94 are independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 92 With R 93 Together they form -CH2CH2-, or R 94 With R 95 Together they form -CH2CH2-.

39. The compound according to claim 37 or 38, and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R 91 Selected from R 13 , or R 91 -R 95 One of the following is selected from R 13 .

40. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (IV') or formula (V'): Among them, R a , R 91 Same definition as above; Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

41. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (VI) or formula (VII): Wherein, the "NH" in the -CH2C(=O)NH- is optionally replaced by R 14 replace; R a , R2, R 91 , R 14 , L is defined as above; R 96 -R 99 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 , -R 21 NHC(=O)R 22 , -R 21 C(=O)NHR 22 , -R 21 C(=O)OR 22 , -R 21 OC(=O)R 22 , -R 21 S(=O)2R 22 , -R 21 S(=O)2NHR 22 、C1-C6 alkyl、C1-C6 Alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; R 96 -R 99 Any two adjacent ones can combine to form a ring; Preferably, the R 96 -R 99 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 96 -R 99 Any two adjacent groups may combine to form a cycloalkyl group; more preferably, the R 96 -R 99 are independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 96 With R 97 Together they form -CH2CH2-, or R 98 With R 99 Together they form -CH2CH2-.

42. The compound according to claim 41 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8alkyl or -S(=O)2C1-C8alkyl, the C1-C8alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl is optionally substituted with one or more R9 selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy or aryl; The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

43. The compound according to claim 42 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)C H2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O )OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH, -C(=O)NHCH2OH, -C(=O )NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2C H2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2CH2NH2, -S(=O)2C H2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2CH2CH2O H, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH.

44. The compound according to any one of claims 41 to 43 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from R 14 , or the R 91 Selected from R 13 , or the R 96 -R 99 One of the following is selected from R 13 .

45. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (VI') or formula (VII'): Among them, R a , R2, R 91 Same definition as above; Preferably, said R2 is selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n ; Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

46. ​​The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (VIII): Among them, R1, Q, R2, R 91 , L is defined as above; R 100 -R 103 are independently selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 , -R 21 NHC(=O)R 22 , -R 21 C(=O)NHR 22 , -R 21 C(=O)OR 22 , -R 21 OC(=O)R 22 , -R 21 S(=O)2R 22 , -R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; R 96 -R 99 Any two adjacent ones can combine to form a ring; Preferably, the R 100 -R 103 are independently selected from: hydrogen, R 13 , C1-C6 alkyl, or R 100 -R 103 Any two adjacent groups may combine to form a cycloalkyl group; more preferably, the R 100 -R 103 are independently selected from: hydrogen, methyl, ethyl, hydroxyl, R n 、-OR n , or R 100 With R 101 Together they form -CH2CH2-, or R 102 With R 103 Together they form -CH2CH2-.

47. The compound according to claim 46 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from: hydrogen, R 14 , C1-C8 alkyl, C3-C 10 Cycloalkyl, -C(=O)C3-C 10 Cycloalkyl, -C(=O)C1-C8alkyl or -S(=O)2C1-C8alkyl, the C1-C8alkyl, C3-C 10 Cycloalkyl and -C(=O)C3-C 10 The cycloalkyl or alkyl portion of a cycloalkyl, -C(=O)C1-C8 alkyl or -S(=O)2C1-C8 alkyl is optionally substituted with one or more R9 selected from the group consisting of hydrogen, halogen, amino, cyano, carboxyl, C1-C6 alkyl, C1-C6 alkoxy or aryl; The R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; The R m Selected from: hydrogen, -C1-C4 alkyl.

48. The compound according to claim 47 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: R2 is selected from the group consisting of hydrogen, methyl, ethyl, -SO2CH3, -COCH3, -CO-isopropyl, -CO-cyclopropyl, isopropyl, cyclopropyl, 2-methoxyethyl, 2-cyanoethyl, phenyl, naphthyl, benzyl, 2-phenylethyl, 1-naphthylmethyl, 2-naphthylethyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O) CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C (=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O)OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)O CH2CH2CH2SH, -C(=O)NHCH2OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C( =O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH, -S(=O)2CH2OH, -S(=O)2CH2CH2OH, -S(=O)2CH2CH2CH2OH, -S(=O)2CH2NH2, -S(=O)2CH2 CH2NH2, -S(=O)2CH2CH2CH2NH2, -S(=O)2CH2SH, -S(=O)2CH2CH2SH, -S(=O)2CH2CH2CH2SH, -S(=O)2NHCH2OH, -S(=O)2NHCH2CH2OH, -S(=O)2NHCH2 CH2CH2OH, -S(=O)2NHCH2NH2, -S(=O)2NHCH2CH2NH2, -S(=O)2NHCH2CH2CH2NH2, -S(=O)2NHCH2SH, -S(=O)2NHCH2CH2SH, -S(=O)2NHCH2CH2CH2SH;Preferably, R2 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl, benzyl, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2CH2SH, -C(=O)CH2OH, -C(=O)CH2CH2OH, -C(=O)CH2CH2CH2OH, -C(=O)CH2NH2, -C(=O)CH2CH2NH2, -C(=O)CH2CH2CH2NH2, -C(=O)CH2SH, -C(=O)CH2CH2SH, -C(=O)CH2CH2CH2SH, -C(=O)OCH2OH, -C(=O)OCH2CH2OH, -C(=O)OCH2CH2CH2OH, -C(=O)OCH2NH2, -C(=O)OCH2CH2NH2, -C(=O) OCH2CH2CH2NH2, -C(=O)OCH2SH, -C(=O)OCH2CH2SH, -C(=O)OCH2CH2CH2SH, -C(=O)NHCH2 OH, -C(=O)NHCH2CH2OH, -C(=O)NHCH2CH2CH2OH, -C(=O)NHCH2NH2, -C(=O)NHCH2CH2NH2, -C(=O)NHCH2CH2CH2NH2, -C(=O)NHCH2SH, -C(=O)NHCH2CH2SH, -C(=O)NHCH2CH2CH2SH. ; 49. The compound according to any one of claims 46 to 48 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R2 is selected from R 14 , or the R 91 Selected from R 13 , or the R 100 -R 103 One of the following is selected from R 13 .

50. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (VIII'): Among them, R1, Q, R2, R 91 Same definition as above; Preferably, said R2 is selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n ; Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m .

51. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (XI): Wherein, the "NH" in the -C(=O)NHCH2- is optionally replaced by R 14 replace; R a , R 14 , R 91 , a2 is defined as above; R 104 Selected from: hydrogen, R 13 , halogen, cyano, amino, nitro, -R 21 C(=O)R 22 , -R 21 NHC(=O)R 22 , -R 21 C(=O)NHR 22 , -R 21 C(=O)OR 22 , -R 21 OC(=O)R 22 , -R 21 S(=O)2R 22 , -R 21 S(=O)2NHR 22 , C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(C1-C6 alkyl)amine, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, 5-6 membered heteroaryl containing 1-3 heteroatoms, or 3-10 membered heterocyclyl containing 1-3 heteroatoms, wherein the alkyl, alkoxy, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl is optionally substituted by a group selected from halogen, cyano, C1-C3 alkyl or C1-C3 alkoxy; Preferably, the R 104 Selected from: hydrogen, R 13 , halogen, C1-C6 alkyl, C1-C6 haloalkyl; More preferably, the R 104 Selected from: hydrogen, F, Cl, Br, methyl, ethyl, trifluoromethyl, hydroxyl, R n 、-OR n .

52. The compound according to claim 51 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R n Selected from: C1-C8 alkyl substituted with hydroxyl, thiol or amino; More preferably, the R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; most preferably, R n Selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH.

53. The compound according to any one of claims 51-52 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R 91 Selected from R 13 , or the R 104 One of the following is selected from R 13 .

54. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The compound is a compound represented by formula (XI'): Among them, R a , R 91 , R 104 Same definition as above; Preferably, the R 91 Selected from: hydroxyl, R n 、-OR n 、-NR m R n 、-NR n -C(=O)R m 、-NR n -S(=O)2R m ; Preferably, the R 104 Selected from: hydroxyl, R n 、-OR n .

55. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R1 is selected from: a C(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-, R a CHR9CH2-、R a CHCHR9-; wherein R9 is selected from: hydrogen, R 13 ; said R 13 Selected from: hydroxyl, thiol, amino, R n ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; R a Selected from: phenyl, naphthalene-1-yl, naphthalene-2-yl, carbazole-9-yl, 1-azacarbazole-9-yl, 2-azacarbazole-9-yl, 1,8-diazacarbazole-9-yl, indol-1-yl, 2,3-dihydro-indol-1-yl, 7-azaindol-1-yl, 2,3-dihydro-7-azaindol-1-yl, phenoxazine-10-yl, fluoren-9-yl, quinolin-4-yl, quinolin-5-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, isoquinolin-1-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-8-yl, isoquinolin-1-yl, isoquinolin-1-yl, isoquinolin-2-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl, isoquinolin-8 ...3-yl, isoquinolin-4-yl, isoquin 8-yl, 1,2,3,4-tetrahydro-1,8-naphthyridin-1-yl, 1,2,3,4-tetrahydroquinolin-1-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 5-(8-quinolin-yl)-pyridin-2-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1,3,4-triazol-1-yl, bicyclo[1.1.1]pentan-1-yl, norbornan-1-yl, adamantane-1-yl; or R a Selected from: 5-(1-isoquinolin-yl)-pyridin-2-yl; R a Optionally substituted with one or more R9 selected from: R 13 , F, Cl, Br, cyano, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, phenyl, naphth-1-yl, naphth-2-yl; the R 13 Selected from: hydroxyl, thiol, amino, R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; said R m Selected from: hydrogen, -C1-C4 alkyl; Q is selected from: -NR2-, The R2 is selected from: hydrogen, R 14 , C1-C8 alkyl; said R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; said R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; said R m Selected from: hydrogen, -C1-C4 alkyl; Said Select one of the following structures: wherein each R9 is independently selected from: hydrogen, R 13 ; said R 13 Selected from: hydroxyl, thiol, amino, R n ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; Each a1 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, each a2 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8; The T and Z are independently selected from: a chemical bond, a methylene group, and 1,2-ethylene; The U is selected from: C1-C6 alkylene, 1,4-phenylene, the 1,4-phenylene is optionally substituted by one or more R9; the R9 is selected from: hydrogen, amino, hydroxyl, thiol, R 13 ; said R 13 Selected from: R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; said R m Selected from: hydrogen, -C1-C4 alkyl; Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-NR2(CH2) b -; L is selected from: -(CR7R8) o -, -C(=O)-; said R7-R8 are independently selected from: hydrogen; The R3-R5 are independently selected from: hydrogen; The R6 is selected from: hydrogen; b is selected from: 0, 1, 2, 3, 4 or 5; n is selected from: 0, 1, 2 or 3; m is selected from: 0, 1, 2, 3 or 4; oSelected from:

1.

56. The compound according to claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that: The R1 is selected from: a C(=O)-、R a CHR9C(=O)-、R a CHR9CH2C(=O)-、R a CHCHR9C(=O)-、R a -、R a CHR9-, R a CHR9CH2-、R a CHCHR9-; wherein R9 is selected from: hydrogen, R 13 ; said R 13 Selected from: hydroxyl, thiol, amino, R n ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; The R a Selected from the following groups: or Q is selected from: -NR2-, The R2 is selected from: hydrogen, R 14 , C1-C8 alkyl; said R 14 Selected from: R n 、-C(=O)R n 、-C(=O)OR n 、-C(=O)NR m R n 、-S(=O)2R n 、-S(=O)2NR m R n ; said R n is selected from: -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2NH2, -CH2CH2NH2, -CH2CH2CH2NH2, -CH2CH2CH2CH2NH2, -CH2SH, -CH2CH2SH, -CH2CH2CH2SH, -CH2CH2CH2SH; said R m Selected from: hydrogen, -C1-C4 alkyl; Said Select one of the following structures: wherein each R9 is independently selected from: hydrogen, R 13 ; said R 13 Selected from: hydroxyl, thiol, amino, R n ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; Each a1 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, each a2 is independently selected from the group consisting of: 0, 1, 2, 3, 4, 5, 6, 7, 8; The T and Z are independently selected from: a chemical bond, a methylene group, and 1,2-ethylene; The U is selected from: C1-C6 alkylene, 1,4-phenylene, the 1,4-phenylene is optionally substituted by one or more R9; the R9 is selected from: Hydrogen, amino, hydroxyl, thiol, R 13 ; said R 13 Selected from: R n 、-OR n 、-OC(=O)R n 、-NR m R n 、-NR m -C(=O)R n 、-NR n -C(=O)R m 、-NR m -S(=O)2R n 、-NR n -S(=O)2R m ; said R n Selected from: C1-C4 alkyl substituted with hydroxyl, thiol or amino; said R m Selected from: hydrogen, -C1-C4 alkyl; Y is selected from: chemical bond, -C(=O)NH(CH2) b -, -NHC(=O)(CH2) b -、-NR2(CH2) b -; L is selected from: -(CR7R8) o -, -C(=O)-; said R7-R8 are independently selected from: hydrogen; The R3-R5 are independently selected from: hydrogen; The R6 is selected from: hydrogen; b is selected from: 0, 1, 2, 3, 4 or 5; n is selected from: 0, 1, 2 or 3; m is selected from: 0, 1, 2, 3 or 4; oSelected from:

1.

57. The compound of claim 1 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes and prodrugs thereof, characterized in that It has the following structure:

58. A pharmaceutical composition, characterized in that It comprises a pharmaceutically acceptable carrier and the compound according to any one of claims 1 to 57 and its pharmaceutically usable salts, solvates, stereoisomers, isotopes and prodrugs thereof.

59. The pharmaceutical composition according to claim 58, characterized in that The pharmaceutical composition may also contain a MYC inhibitor, a DNA methyltransferase inhibitor or a Bcl-2 selective inhibitor.

60. The pharmaceutical composition according to claim 59, characterized in that The MYC inhibitor is any one or more of OMO-103, APTO-253, PLX-51107, DCR-M1711, Oncomyc-NG, INX-3280, PU-27, GSK-3179106, cholesterol butyrate and NSC-165563; the DNA methyltransferase inhibitor is any one or more of 5-azacytidine, RG108, SGI-1027, GSK3685032, CM272, Bobcat339 hydrochloride, Decitabine (NSC 127716), Thioguanine (NSC 752), 2'-Deoxy-5-Fluorocytidine, Procainamide HCl or Zebularine (NSC 309132); the Bcl-2 selective inhibitor is Venetoclax (ABT-199), S55746, BDA-366, Obatoclax Any one or more of Mesylate (GX15-070), HA14-1 or APG-2575 (CAS No. 2180923-05-9).

61. The pharmaceutical composition according to claim 59, characterized in that The pharmaceutical composition comprises a Bcl-2 selective inhibitor, and the Bcl-2 selective inhibitor is Venetoclax (ABT-199), Obatoclax Mesylate (GX15-070) or APG-2575 (CAS No. 2180923-05-9).

62. Use of the compound of any one of claims 1-57 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs and the pharmaceutical composition of any one of claims 58-61 in the preparation of any one or at least two or more protein degraders of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7.

63. Use of the compound of any one of claims 1-57 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs and the pharmaceutical composition of any one of claims 58-61 in the preparation of drugs for treating diseases related to protein disorders of any one or at least two or more of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7.

64. Use of the compound of any one of claims 1-57 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs and the pharmaceutical composition of any one of claims 58-61 in treating diseases related to protein disorder of any one or at least two or more of c-Myc, N-myc, GSPT1, CK1α, IKZF (1 / 2 / 3), AR and AR-V7.

65. The use according to claim 63 or 64, characterized in that The protein disorder is selected from protein overexpression.

66. The use according to claim 63 or 64, characterized in that The protein disorder-related disease is selected from: cancer, cardiovascular and cerebrovascular diseases, and viral infection-related diseases.

67. The use according to claim 66, characterized in that The cancer is selected from the group consisting of leukemia, lymphoma, malignant glioma, medulloblastoma, melanoma, multiple myeloma, myelodysplastic syndrome, liver cancer, lung cancer, kidney cancer, pancreatic cancer, oral cancer, gastric cancer, esophageal cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, breast cancer, colon cancer, rectal cancer, bladder cancer, cervical cancer, ovarian cancer, prostate cancer, rhabdomyosarcoma, osteosarcoma, chondrosarcoma; the viral infection-related disease is selected from the group consisting of HIV, hepatitis B, hepatitis C, hepatitis A, influenza, epidemic encephalitis B, herpes; the leukemia includes chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute non-lymphocytic leukemia (ANLL).

68. Use of the compound according to any one of claims 1 to 57 and its pharmaceutically acceptable salts, solvates, stereoisomers, isotopes, prodrugs and the pharmaceutical composition according to any one of claims 58 to 61 in the preparation of a medicament for treating acute myeloid leukemia (AML).

69. The use according to claim 68, characterized in that The pharmaceutical composition comprises a Bcl-2 selective inhibitor, and the Bcl-2 selective inhibitor is Venetoclax (ABT-199), Obatoclax Mesylate (GX15-070) or APG-2575 (CAS No. 2180923-05-9).

70. The compound described in any one of claims 1-57 and its pharmaceutically acceptable salt, solvate, stereoisomer, isotope and prodrug thereof are used for preparing protein hydrolysis targeting chimera (proteolysis targeting chimera, PROTAC), antibody-drug conjugate (antibody-drug conjugate, ADC), peptide-drug conjugate (peptide-drug conjugate, PDC) or small molecule drug conjugate (small molecular-drug conjugate, SMDC) in use.